

# INDIAN CONSENSUS GUIDELINE ON ADULT IMMUNIZATION

Editors:


Dr. Girish Mathur

Dr. Agam Vora



## In Association with

- Cardiological Society of India (CSI)
- Clinical Infectious Diseases Society (CIDS)
- Federation of Obstetric and Gynecological Societies of India (FOGSI)
- Geriatric Society of India (GSI)
- Heart Failure Association of India (HFAI)
- Indian Association of Preventive and Social Medicine (IAPSM)
- Indian Chest Society (ICS)
- Indian Medical Association (IMA)
- Indian Rheumatology Association (IRA)
- Indian Society of Critical Care Medicine (ISCCM)
- Indian Society of Nephrology (ISN)
- Indian Society of Oncology (ISO)
- Research Society for Study of Diabetes in India (RSSDI)



# Preface

It is with immense pride and a sense of accomplishment that we present to you a monumental stride in the realm of healthcare – Indian Consensus Guideline on Adult Immunization developed by the Association of Physicians of India (API).

This endeavour marks a historic collaboration, bringing together representatives from 13 diverse professional organizations namely Cardiological Society of India, Clinical Infectious Disease Society, Federation of Obstetric & Gynaecological Societies of India, Geriatric Society of India, Heart Failure Association of India, Indian Association of Preventive & Social Medicine, Indian Chest Society, Indian Medical Association, Indian Rheumatology Association, Indian Society of Critical Care Medicine, Indian Society of Nephrology, Indian Society of Oncology, Research Society of Study of Diabetes in India. For the first time, these collective efforts converge to address a crucial aspect of public health – adult immunization.

As we navigate the complexities of healthcare in India, it is evident that the landscape is evolving rapidly. The emergence of new medical challenges, coupled with the increasing geriatric population, necessitates a proactive approach to immunization. With projections indicating that nearly 23% of our population will belong to the 50-plus age group by the end of the next decade, the significance of adult immunization cannot be overstated.

The myths and misconceptions surrounding adult vaccination persist, both among citizens and healthcare providers. It is against this backdrop that API has been actively engaged in the field for over a decade. We have published guidelines, disseminated knowledge through articles in our esteemed Journal (JAPI), and now, with these Consensus Guideline, we aim to bridge the existing gaps in understanding and implementation.

Under the astute leadership of Dr. Girish Mathur, representatives from various medical associations convened, engaging in rigorous brainstorming sessions, comprehensive literature reviews, and meticulous comparisons of national and international guidelines. The outcome is a comprehensive resource that not only addresses the concerns of healthcare providers but also provides clear, consensus-based recommendations for each vaccine.

These guideline delve into the specifics of each available vaccine, offering insights into recommended practices and providing a unified voice amid the existing plethora of guidelines. We acknowledge the challenges healthcare workers face, particularly when managing patients with multiple co-morbidities. Hence, these guideline offer a consolidated approach, ensuring clarity in decision-making for healthcare providers.

As the Secretary of the Association of Physicians of India, I extend my gratitude to all the contributors, collaborators, and stakeholders who have played a pivotal role in making this initiative a reality. Your dedication and commitment to advancing healthcare in our nation are commendable.

I invite you to delve into this Consensus Guideline, share your insights, and actively participate in the ongoing dialogue. Your feedback is invaluable as we strive to continually update and enhance this guideline to meet the dynamic healthcare landscape.

Wishing you an enlightening and enriching journey through these guidelines.

Warm regards,

**Dr. Agam Vora**  
Secretary General  
Association of Physicians of India

**Dr. Girish Mathur**  
Immediate Past President  
Association of Physicians of India



Inauguration of the Indian Consensus Guideline  
on Adult Immunization by  
the honourable Vice President of India  
**Shri Jagdeep Dhankhar**  
on the 22<sup>nd</sup> February at APICON 2024, New Delhi, India  
in the presence of Dr. Girish Mathur, Dr. Milind Nadkar,  
Dr. Rajesh Upadhyay, and Dr. Agam Vora.

# Association of Physicians India



## Dr. Girish Mathur

MD, FICP, FRCP (Lon, Glas, Edin), FACP, FIACM, FRSSDI  
Senior Consultant, Internal Medicine, Kota  
Immediate Past President, Association of Physicians  
of India (API)

## Dr. Milind Nadkar

MBBS, MD (Internal Medicine)  
Professor and Head, Department of Medicine,  
Chief of Rheumatology Services, Seth GS Medical  
College and KEM Hospital, Mumbai  
President, Association of Physicians of India (API)

## Dr. Agam Vora

MD, Chest & TB, FICP, FCCP  
(USA) and (India), FGS, FRCP (London)  
Medical Director - Vora Clinic & Brahmakumari  
Global Hospital, Mumbai  
Hon. General Secretary, Association of  
Physicians of India (API)

## Dr. Jyotirmoy Pal

MD, FRCP, FICP, FACP, WHO Fellow  
Professor of Medicine, COM and Sagore Dutta  
Medical College, Kolkata  
Dean, Indian College of Physicians  
President Elect, Association of Physicians of  
India 2024 -25

## Dr. Mangesh Tiwaskar

MD (Medicine), FRCP (Lon/Glas/Edin./Ire.), FACP, FICP,  
FGSI, FDI, Dip. in Advanced Diabetology (Denmark)  
Consultant Physician and Diabetologist, Shilpa  
Medical Research Center, Mumbai  
Editor-in-Chief – Journal of Association of  
Physicians of India  
On Editorial Board – Medicine Update,  
International Journal of Diabetes  
Guest Editor – Insulight Journal,  
World Journal of Anaemia  
MRCP Examiner for Royal Colleges of Physicians UK

## Dr. Shashank R. Joshi

MD, DNB, DM (Endocrinology), FACC, FACE, FACP, FRCP  
Consultant Endocrinologist, Lilavati Hospital, Mumbai  
Honoured Padma Shri by the Government of India  
President of the Indian Academy of Diabetes,  
Chairman, AACE (India Chapter)  
Past President of API, ESI, Past Dean of ICP

## Dr. Amit A. Saraf

MD, FRCP (London, Edinburgh, Glasgow),  
FACP (Philadelphia), FICP, FCPS  
Director, Dept of Internal Medicine  
Jupiter Hospital, Mumbai  
Hon. Treasurer, Association of  
Physicians of India (API)

# Cardiological Society of India



## Dr. Vijay Harikisan Bang

MBBS, MD, DM, FCSI, FESC, FACC, FSCAI (USA)

Senior Interventional Cardiologist |  
Heart Care Services

Fellow of American College of Cardiology,  
Cardiological Society of India, European Society  
of Cardiology, Society for Cardiac Angiography  
and Intervention

President of Cardiology Society of India (CSI)

## Dr. Debabrata Roy

MBBS, MD, DM (Cardiology)

Member of Cardiological Society of India, Association of  
Physicians of India, Indian Medical Association, American  
College of Cardiology, European Society of Cardiology,  
Coronary Angiography and Intervention, American Heart  
Association, American Heart Association, Secretary of  
Cardiological Society of India-West Bengal branch.

Consultant at the prestigious Rabindranath Tagore  
International Institute of Cardiac Sciences in Kolkata, India.

Honorary Secretary of Cardiology Society of India (CSI)

## Dr. Pratap Chandra Rath

MBBS, MD (General Medicine), DM (Cardiology)

Director and HOD Cardiology, Apollo Hospitals, Hyderabad  
and Bhubaneswar.

Fellow of the American College of Cardiology, European  
Society of Cardiology and Indian College of Cardiology.  
Visiting faculty of the Dept. of Cardiology, University of  
Rouen, France; Adjunct Professor in the School of  
Medicine, The University of Queensland, Australia;  
Honorary Visiting Professor – Gandhi Medical College,  
Bhopal, Madhya Pradesh. Health Sciences, at the  
University of Queensland, Australia, and the Apollo  
Hospitals Educational and Research Foundation (AHERF).  
Course Director at Hyderabad Valves and the Course  
Co-director at India Live, and Hyderabad Live.

President Elect of Cardiology Society of India (CSI)

# Clinical Infectious Diseases Society



## Dr. Venkatasubramanian Ramasubramanian

MD, FRCP (Glas), DTM & H (Lon), DGUM (Lon)  
Fellow of the European Society of Clinical Microbiology & Infectious Diseases  
Fellow of the Infectious Diseases Society of America  
Director - The Capstone Clinic  
Consultant Infectious Diseases & Tropical Medicine, Apollo Hospitals  
Adjunct Prof Infectious Diseases - Sri Ramachandra Institute of Higher Education & Research, The Tamilnadu Dr MGR Medical University, Saveetha Medical College and Apollo Hospitals Educational & Research Foundation  
Past President - Clinical Infectious Diseases Society of India

## Dr. Pricilla Rupali

MD, DTMH, FRCP  
Senior Professor and Head of the Department of Infectious Diseases at Christian Medical College in Vellore, India.  
Hon. Secretary, The Clinical Infectious Diseases Society (CIDS)

## Dr. Dilip Mathai

MBBS, MD, PhD, FCAMS, FRCP, (Lond),  
FICP, FIDSA, Hon. FFTM RCPS (Glasg)  
Postgraduate Research Institute for Medical Education (PRIME)  
Pondicherry Institute of Medical Sciences (PIMS) Puducherry  
Madras Medical Mission (MMM) Hospital, Chennai  
Director of Medical Education and Quality: Naruvi Hospitals, Vellore  
Founder Director, Center for Infectious Diseases, Vellore  
President, AIDS Society of India 2023  
Member Governing Council, Clinical Infectious Diseases Society-India  
Convener NBE, FNB - ID Specialty Board  
Member ANBAI, Training the Trainers NBE Teachers Board

# Federation of Obstetric and Gynaecological Societies of India



## Dr. Hrishikesh Pai

MD FRCOG (UK-ons) MSc (USA), FCPS, FICOG  
Trustee, International Federation of Obstetrics & Gynecology (FIGO) Asia Oceania Region 2023-25  
Prof of Reproductive Medicine, D Y Patil University  
Medical Director, Bloom IVF Group  
Consultant Gynecologist Lilavati Hospital Mumbai and Fortis Hospital New Delhi and Mohali  
Immediate past President, Federation of Obstetrics and Gynaecological Societies of India (FOGSI)

## Dr. Jaydeep Tank

MBBS, MD, DGO, DNB, FCPS (Mid. & Gynae)  
Obstetrician and Gynecologist, IVF Consultant  
Past Secretary General Federation of Obstetrics and Gynaecological Societies of India (FOGSI)  
Vice President, Mumbai Obstetrics and Gynaecological Society (MOGS),  
Chair, International Federation of Obstetrics and Gynaecology (FIGO) Working Group for safe abortion.  
Deputy Secretary, Asia Oceania Federation of Obstetrics and Gynaecology (AOFOG)  
Ex Chair, Publication and News letter committee Asia Oceania Federation of Obstetrics and Gynaecology (AOFOG)  
Ex Chair, Reproductive Endocrinology and Infertility Committee – Asia Oceania Federation of Obstetrics and Gynecology (AOFOG)  
Ex Chairman, MTP committee (FOGSI) 2004 - 09.  
Vice President, Forum For Enhancement of Quality in Healthcare. (FEQH)  
President Elect, of Federation of Obstetric and Gynaecological Societies of India (FOGSI)

## Dr. Nandita Palshetkar

MD, FCPS, FICOG, FRCOG (UK)  
Medical Director and Founder Bloom IVF  
Professor in OBGY at D. Y. Patil Medical College, Navi Mumbai  
Teacher for Super Specialty Degree, Reproductive Medicine MUHS  
Organizing chairperson - AICOG 2025 Mumbai. (ALL INDIA CONGRESS OF OBSTETRICS & GYNAECOLOGY)  
President – Federation of Obstetrics and Gynaecological Societies of India - FOGSI (2019-2020)  
President – Indian Society of Assisted Reproduction – ISAR (2022-2024)  
President – Indian Association of Gynaecological Endoscopy – IAGE (2017-2018)  
President – Association of Maharashtra Societies of Obstetrics and Gynaecology, AMOGS (2020 - 2022)  
President – Mumbai Obstetrics and Gynaecological Society - MOGS (2016-2017)  
Chairperson – Maharashtra Chapter of ISAR – MSR (2016 - 2018)  
FOGSI Representative to FIGO (2022-Present)  
FIGO Project Head - PPH – AMPLI  
Co-Chair - REI Committee of SAFOG

## Dr. Madhuri Patel

MD, IVF specialist  
Gynecologist and Obstetricians Mumbai.  
Secretary General, Federation of Obstetric and Gynaecological Societies of India (FOGSI)

# Geriatric Society of India



## Dr. Kaushik Ranjan Das

MBBS; DFM; DGC;PGCC(GM)

Founder Secretary, GSI Eastern Zonal Branch,  
Founder Vice Chairman GSI West Bengal Branch.  
President Geriatric Society of India.

## Dr. A K Singh

Specialty: Internal Medicine

Member of IMA

Member of IPA

President Elect of Geriatric Society of India (GSI)

## Dr. O. P. Sharma

MBBS, MD

Sr. Consultant, Geriatric Medicine at Indraprastha Apollo  
Hospitals, New Delhi

Association of Physicians of India

Cardiology Society of India

Geriatric Society of India

Association of Gerontology, India

Honorary Secretary, Geriatric Society of India (GSI)

# Heart Failure Association of India



**HEART FAILURE  
ASSOCIATION OF INDIA**

*Improving Heart Failure Care*

## Dr. Abraham Oomman

MD, DM (Cardiology)

DNB (Cardiology) MNAMS, FSCAI, FACC, FHFA

Senior Consultant Cardiologist & HF Specialist,  
Apollo Hospitals, Chennai

Presented Scientific Paper at the American Heart  
Association & European Society of Cardiology  
Scientific Sessions.

President, Heart Failure Association of India (HFAI)

## Dr. Harikrishnan Sivadasanpillai

MD, MBBS, DM, FRCP Professor, Cardiology

Member of Pulmonary Vascular Research Institute, UK,  
Cardiological Society of India

PH - LEADER (The Public Health Leadership and  
Implementation Academy) Programme - Emory University,  
Atlanta, USA - 2014 -15.

Commonwealth Fellowship in Coronary Interventions,  
Leeds University,U.K.-2005-6.

Past President, Heart Failure Association of India (HFAI)

# Indian Association of Preventive and Social Medicine



## Dr. Madhu Gupta

MBBS, MD (Community Medicine), PhD (Health, Medicine, Life Sciences, Maastricht University, The Netherlands), Member American Academy of Family Physicians, FIAPSM, MIAPSM, MIPHA

Professor of Community Medicine, Department of Community Medicine and School of Public Health, Postgraduate Institute of Medical Education & Research (PGIMER)

Chairperson, Indian Association of Preventive and Social Medicine (IAPSM)

## Dr. Lalit Sankhe

MBBS, MD

Associate Professor, Department of Community Medicine, Grant Medical College and Sir J.J. Group of Hospitals, Mumbai

Member, Indian Association of Preventive and Social Medicine (IAPSM)

## Dr. Veena Kamath

MBBS, MD

Head of the Department of Community Medicine, Kasturba Medical College, Manipal

Member, Indian Association of Preventive and Social Medicine (IAPSM)

# Indian Chest Society



## ICS

INDIAN CHEST SOCIETY

## Dr. Richa Gupta

MD, FCCP

Professor and Head of the department of Respiratory Medicine, Christian Medical College Hospital, Vellore, TN.

## Dr. Deepak Talwar

MD, DM, FCCP,

Senior Consultant & Chairman - Metro Respiratory Center Pulmonology & Sleep Medicine  
Member, Indian Society of Critical Care Medicine

Faculty, Academy for Infection Management

Member, International Society of Critical Care Medicine (USA)

Member, European Society of Enteral & Parental Nutrition (Europe)

Member, European Respiratory Society (Europe)

Instructor for FCCS Course

# Indian Medical Association



## Dr. R V Asokan

A practising General Physician running a 43 bedded hospital, in Punalur, in Kollam district of Kerala State. Former Secretary General, IMA and Chairman, End TB Initiative. He was the IMA State Secretary of Kerala for 3 years and later it's State President.

National President – Indian Medical Association (IMA)

## Dr. Jayesh Lele

Ex-National Secretary,

IMA Hospital Board of India, 2016-20

Hon. Secretary General, IMA HQ 2020-22

President IMA Maharashtra 2015-16

Senior National Vice President, Indian Medical Association (IMA)

## Dr. Anilkumar J Nayak

MBBS, MS (Orthopaedic) Gold Medalist

Dean, Medical Faculty Hemchandracharya North Gujarat University (HNGU), Patan

Professor & Head of the Department, Department of Orthopaedic Surgery, Banas Medical College and Research Center, Palanpur, Banaskantha District Senator, H.N.G. University, Patan

Hony. Secretary, Indian Red Cross Society, Mehsana District Branch

Co-ordinator, Indian Red Cross Society, North Gujarat Zone

Hon. Secretary General, Indian Medical Association (IMA)

# Indian Rheumatology Association



## Dr. Chandrashekara S

MD, DM (Clinical Immunology)

Consultant Rheumatologist

ChanRe Rheumatology & Immunology Center & Research, Bengaluru

President, Indian Rheumatology Association

## Dr. B G Dharmanand

MBBS, MD (Internal Medicine), DM (Rheumatology/Clinical Immunology)

Consultant Rheumatologist Manipal Hospital

Past President, IRA, Karnataka chapter

Immediate Past President, Indian Rheumatology Association

## Dr. Vinod Ravindran

MD, MSc-Rheumatology (UK),

CCT-Rheumatology (UK), FRCP

Consultant Rheumatologist, Centre for Rheumatology, Calicut, Kerala

Adjunct Professor of Medicine, KMC, MAHE, Manipal, Karnataka

Secretary, Indian Rheumatology Association

## Dr. Aman Sharma

MD, FRCP(London)

Professor, Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh.

President-Elect, Indian Rheumatology Association

# Indian Society of Critical Care Medicine



## Prof. Sheila Nainan Myatra

MD, FCCM, FICCM

Professor of Critical Care Medicine, Tata Memorial Hospital, Mumbai, India.

Chair of the Intensive & Critical Care Medicine Committee of the World Federation of Societies of Anaesthesiologists (WFSA)

President of the Indian Society of Critical Care Medicine (ISCCM) 2023-2024

## Dr. Rajesh Pande

B.SC, MBBS, MD, PDCC(Cardiac Anaesthesia), FCCM, FICCM

Presently working as a Principal Director & HOD in Critical Care Medicine Department at BLK-Max Super Speciality Hospital, New Delhi.

Consultant in Critical Care Medicine & Casualty  
Co-ordinator: Sir Ganga Ram Hospital, New Delhi

Ex-Chairman, Indian Society of Critical Care Medicine, Delhi-Noida Chapter

Ex-Vice Chancellor, Indian College of Critical Care Medicine  
General Secretary National, Indian Society of Critical Care Medicine

# Indian Society of Nephrology



## Dr. Sanjeev Gulati

MBBS, MD(Paed), DNB(Paed)

DM(Nephrology), DNB(Nephrology)

Executive Director Nephrology and Kidney Transplant Fortis Group of Hospitals NCR

Ex-Vice President, Indian Society of Organ Transplantation

Secretary, North Zone Chapter of the Indian Society of Nephrology

Ex-President, Delhi Nephrology Society

President, Indian Society of Nephrology (ISN)

## Dr. H.S Kohli

MD,DM,FAMS,FISN, FRCP (London)

Nephrologist Renal Specialist,

The Institute of Medical Education and Research General Hospital, Chandigarh, Punjab

President Elect, Indian Society of Nephrology (ISN)

## Dr. Umesh Khanna

MBBS, DNB

Nephrologist/Renal Specialist Member,  
Indian Society of Nephrology.

Member, Indian Society of Organ Transplantation.

Member, National Kidney Foundation, India. Served on the Managing Committee and as Chairman of Public Education Cell.

Assistant Editor, Journal of Renal Sciences.

Editorial Board member: Enigma - magazine of Goregaon Medical Association.

## Dr. Shyam Bihari Bansal

DM, FISN, FISOT, FASN, FRCP (London)

Former Secretary, Delhi Nephrology Society

Executive member, Indian Society of Organ Transplantation

Director and Head, Department of Nephrology

Medanta-Medicity, Gurgaon

Secretary, Indian Society of Nephrology

# Indian Society of Oncology



## Dr. Ramesh S. Bilimagga

MBBS, MD

Medical Director of the HCG Group of hospitals.

He was the National President AROI (Association of Radiation Oncologists of INDIA). Senior Radiation Oncologist with over thirty-seven years of experience in the field. He is a Fellow of International College of Surgeons (Indian Section) and Fellow of Indian College of Radiation Oncology.

President of Indian Society of Oncology (ISO)

## Dr. Arvind Krishnamurthy

MBBS-SB, DNB, MCh (Surgical Oncology),  
MS (General Surgery)

Fellow of The International College Of Surgeons (FICS)

Fellowship of Association Of Indian Surgeons (FAIS)

Member of Indian Medical Association (IMA), Association Of Surgeons Of India (ASI), Indian Society Of Oncology (ISO), Indian Association Of Surgical Oncology (IASO), Association Of Foundation Of Head And Neck Oncology (FHNO), Indian Association Of Bronchology (IAB), Indian Thyroid Society (ITS), Indian Association Of Cardiothoracic Surgeons (IACTS)

Honorary Secretary of Indian Society of Oncology (ISO)

## Dr. Rajendra Toprani

MS, M Ch. (Surgical Oncology)

Senior Consultant, Head & Neck Surgical Oncologist  
Director, Department of Surgical Oncology

Director, Aastha Oncology Associates

Director, HCG Cancer Center, Ahmedabad

Trained Robotic Surgeon and underwent training for Trans Oral Robotic Surgery (TORS) with Prof. Weinstein at UPENN at Philadelphia in 2016.

Fellow at M.D. Anderson Cancer Centre, Houston, USA. His areas of interest are Oral & Laryngeal Cancers, Thyroid and Parotid Tumors. He has expertise in voice preserving Laryngectomies and Trans Oral Endoscopic Laser Surgery (TOLS) for which he attended an advanced workshop in Endoscopic Laser Surgery in Kiel, Germany in 2009.

President Elect of Indian Society of Oncology (ISO)

# Research Society for the Study of Diabetes in India



## Dr. Rakesh Kumar Sahay

MD, DM, FACE, FICP, FAMS  
Associate Editor, IJDDC, Editorial board member of IJEM  
Immediate Past President,  
Endocrine Society of India (2021-22)  
President of South Asian Federation of  
Endocrine Societies (2024-25)  
Section Editor, Tropical Endocrinology,  
Endotext – online textbook of Endocrinology  
President, Research Society for Study of Diabetes in India

## Dr. Sanjay Agarwal

MD, FACE, FACP  
Head, Dept.of Medicine & Diabetes, Ruby Hall,  
Head, Dept.of Diabetes, Obesity & Metabolic  
Diseases, Sahyadri Hospitals  
Secretary General – Research Society for Study of  
Diabetes in India (RSSDI)

## Dr. Brij Mohan Makkar

MD, FIAMS, FICP, FRSSDI, FRCP(GLASG,EDIN), FACP(USA), FACE(USA)  
Member by invitation to American Diabetes Association,  
A member of European Association for Study of Diabetes(EASD),  
European Association for Study of Obesity(EASO),  
and Canadian Obesity Research Network.  
Immediate Past President of National Research Society for  
Study of Diabetes in India (RSSDI)

# Contents

Introduction.....	14
Harmonization of Adult Immunization in India.....	15
Method of Consensus Development.....	16
High Risk Group.....	16
What are Vaccines ? .....	17
Anthrax.....	21
Chickenpox.....	22
Chikungunya.....	23
Cholera.....	24
Corona Virus Disease 2019 (COVID-19).....	26
Diphtheria, Pertussis and Tetanus.....	28
Haemophilus influenzae type b (Hib) Infection.....	29
Hepatitis A.....	30
Hepatitis B.....	32
Human Papilloma Virus.....	33
Influenza.....	34
Japanese Encephalitis.....	35
Measles, Mumps and Rubella.....	36
Meningococcal Disease.....	37
Pneumococcal Disease.....	38
Poliomyelitis.....	40
Rabies.....	41
Respiratory Syncytial Virus.....	42
Typhoid.....	43
Shingles (Herpes Zoster).....	44
Yellow Fever.....	45
Closing the Gap: Bridging the Need for Childhood Vaccines into Adult Healthcare.....	46
Indian Consensus Recommendations.....	47
Indian Consensus Recommendation for Risk Conditions.....	54
Indian Consensus Recommendation Based on Age.....	55
Upcoming Vaccines.....	58
Conclusion.....	62
Appendix.....	63
References.....	78

# Introduction

One of the most economical public health measures now accessible is vaccination. Vaccines help protect the community by halting the transmission of infectious diseases, in addition to preventing the vaccinated person from contracting a potentially serious illness. Immunization is a tried and tested method of managing and eradicating infectious diseases that can be fatal. Furthermore, vaccination is estimated to help avert between 2 and 3 million deaths annually.<sup>1</sup> It is one of the health initiatives with the highest return on investment, and it can reach even the most vulnerable populations.

**India has had a well-defined pediatric immunization schedule active since 1978. It is one of the biggest vaccination campaigns in the world and is called the 'Universal Immunization Program' (UIP).**

**Every year, the UIP aims to immunize about 2.7 crore newborns with all primary doses and an additional 10 crore children between the ages of one and five with booster doses. Additionally, TT vaccinations are given to almost 3 crore expectant mothers annually. The beneficiaries are immunized as part of 90 lakh vaccination sessions annually.**

The Government of India (GoI) observes 16 March as National Vaccination Day to celebrate the efforts towards paediatric vaccination. Considerable work is done in this field to protect our children from Vaccine-Preventable Diseases (VPD). That said, adult vaccination is an area that is greatly neglected.

The prevalence of diabetes and other metabolic Non-communicable Diseases (NCDs) in India is significantly higher than previously believed. Although the diabetes epidemic appears to be stabilizing in the more developed states of the country, it continues to rise in most other states.<sup>2</sup>

NCDs are associated with increased risk of infection and related hospitalizations and

deaths. This situation has serious implications for the nation, highlighting the need to evaluate the need for adult vaccination.

The need for adult immunization is crucial to protect individuals from vaccine-preventable diseases and reduce the burden of illness in the adult population. Here are some key reasons highlighting the importance of adult immunization:

- Vaccines are effective in preventing various infectious diseases, including but not limited to influenza, pneumonia, Shingles (Herpes Zoster), hepatitis, and tetanus.
- VPD can lead to serious health complications, hospitalizations, and even death, particularly in older adults or those with underlying health conditions.
- When a significant portion of the population is immunized, it creates herd immunity, which provides indirect protection to those who are unable to receive vaccines due to medical conditions or age.
- Vaccines not only protect individuals but also help in reducing the transmission of infectious diseases.
- Adult immunization plays a crucial role in maintaining a healthy workforce and preventing disease outbreaks in community settings.
- As individuals age, their immune systems may weaken, making them more susceptible to infections.
- As life expectancy increases and healthcare becomes more accessible, the percentage of the population that is elderly also increases. Given that vaccine-preventable diseases are more likely to be contracted as a result of this demographic shift, immunization campaigns are crucial for

reducing the risks infectious pathogens pose to the public health.

- International travel exposes individuals to different infectious diseases prevalent in other countries.

There is a pressing need to address the issue of adult immunization in India. While several aspects concerning the effectiveness, safety, and financial implications of implementing adult vaccines at a national scale remain unresolved, raising awareness among health planners and healthcare providers about this important issue is important. Most major health societies in India have rolled out their respective adult vaccine programs, however, a standardized schedule for adults is lacking. This is an attempt to have a standardized schedule that one may refer to for adult immunization and a call to the Government of India (GoI) for inclusion of adult immunization in the 'UIP' with focus on specific high-risk subgroups in

increased need of immunization; also, inclusion under reimbursement and insurance (both public and private sector) schemes can play an important role as a milestone in making this dream a reality in the foreseeable future. Since the field of medicine is constantly evolving, physicians are advised to consult the most recent locally approved summary of product characteristics (SmPC) or prescribing information before administering any vaccine.

While every effort was made to provide the most stringent guidance to a clinician for appropriate use of vaccines, local or regional outbreaks similar to the one experienced during the COVID-19 pandemic can take us all by surprise, so one is always advised to refer to the local, regional or national guidance for managing loco-regional outbreaks.

---

## Harmonization of Adult Immunization in India

The synchronization of vaccination guidelines in India from different medical societies marks a significant step towards developing a rational and systematic approach to vaccination. By aligning recommendations and protocols from different medical societies, the aim is to formulate consistent and clear guidance for healthcare professionals and the public. Representatives from multiple medical societies in India were invited to brainstorm and collaborate to come out with a harmonized guidance document that one may refer to in times of need. Medical societies invited include Indian Medical Association (IMA), Research Society for the Study of Diabetes in India (RSSDI), Geriatric Society of India (GSI), Indian Society of Nephrology (ISN), Indian Society of Critical Care Medicine (ISCCM), Indian Chest Society (ICS), Indian Rheumatology Association

(IRA), Heart Failure Association of India (HFAI), Cardiological Society of India (CSI), The Federation of Obstetric and Gynaecological Societies of India (FOGSI), Clinical Infectious Diseases Society (CIDS), Indian Society of Oncology (ISO) and Indian Association of Preventive and Social Medicine (IAPSM).

**This concerted initiative does not merely streamline vaccine distribution, administration and monitoring, but also amplifies India's potential to aptly deal with public health challenges, creating a platform for open communication and knowledge sharing between medical societies. The establishment of a central coordination body with representatives from different societies optimized the synthesis of this guidance document. Government involvement is ess**

essential to create a regulatory framework that promotes collaboration and standardization. All reasonable efforts will be made to obtain endorsement for adult

vaccination as a standard procedure, allowing its integration into national and state-level policies for the efficient application of protocols.

---

## Method of Consensus Development

Through the use of the Nominal Group Consensus methodology, these harmonization efforts guarantee an inclusive decision-making process in which the opinions of all stakeholders are heard. This encourages a fairer and better-informed consensus by preventing any one viewpoint from overshadowing others. Currently, there can be confusion due to the disparate vaccination recommendations from multiple societies.

**Recognizing the urgent need for collaboration, the Association of Physicians of India brought together various societies (as mentioned above) and their representatives for this harmonization project. Stakeholders addressed the unique needs of various patient groups served by different specialties in a series of in-person and virtual roundtable discussions, offering input in person or via email. A thorough literature review was conducted in the hope of creating unified immunization guidance for India, with a focus**

**on adult immunization and future vaccines.**

Through this initiative, national immunization programs were to be in line with international guidelines, such as those provided by the Center for Disease Control (USA) and World Health Organization (WHO). The literature review has established a strong basis for the creation of unified vaccination recommendations in India by incorporating important themes. Using a comprehensive approach guarantees that the recommendations not only tackle the issues surrounding adult vaccination today, but also continue to be flexible in response to changes in the field of vaccine development and international immunization programs. The consensus gains a practical aspect from the collaboration of medical societies, which makes them applicable and efficient in the various healthcare environments throughout the nation.

---

## High Risk Group

In the adult population, a subgroup with a high risk of vaccine-preventable diseases, are individuals with compromised immune systems, such as those suffering from conditions like Human Immunodeficiency Virus (HIV) | Acquired Immunodeficiency Syndrome (AIDS), neoplastic disorders, or post-transplantation states.

Additionally, adults harbouring chronic medical disorders, including cardiovascular, hepatic metabolic, or respiratory disorders, are at an increased risk of serious outcomes following an infection. Advancing years, particularly beyond 65, increases vulnerabilities to certain diseases. Chronic alcoholics (referred to as alcoholism in the tables below) are at risk of a weakening immune system and developing hepatic

disorders, making them susceptible to infectious diseases. Healthcare professionals, due to their occupational exposure, and travelers to regions where particular diseases are endemic, also fall within this high-risk

group, warranting specialized vaccination strategies. For all these reasons, vaccination is crucial for protecting from illnesses that may have serious consequences on an individual's health.

---

## What are Vaccines?


Vaccines are biological substances that stimulate the immune system to develop immunity against specific diseases. They are typically composed of weakened or inactivated forms of pathogens (such as bacteria or

viruses), or fragments of those pathogens. Vaccines can also contain synthetic components that mimic the structure of the pathogen.<sup>3</sup>

### Types of Vaccines Available

1. Live Attenuated Vaccines
2. Inactivated or Dead Vaccines
3. Acellular or Subunit Vaccines
  - a. Toxoid Vaccines
  - b. Conjugate Vaccines
  - c. Split Virion Vaccine
  - d. Protein Subunit Vaccines
4. Recombinant Vaccines
  - a. mRNA vaccines
  - b. pDNA vaccines
5. Viral Vector vaccines

**Figure 1. Vaccines development journey<sup>5</sup>**



## List of vaccines discussed in this consensus

- |                                  |                                 |
|----------------------------------|---------------------------------|
| 1. Anthrax                       | 18. Rabies                      |
| 2. Chickenpox                    | 19. Respiratory Syncytial Virus |
| 3. Chikungunya                   | 20. Measles                     |
| 4. Cholera                       | 21. Mumps                       |
| 5. Corona Virus Disease 2019     | 22. Rubella                     |
| 6. Diphtheria                    | 23. Typhoid                     |
| 7. Pertussis                     |                                 |
| 8. Tetanus                       |                                 |
| 9. Haemophilus Influenzae Type B | 24. Shingles (Herpes Zoster)    |
| 10. Hepatitis A                  | 25. Yellow Fever                |
| 11. Hepatitis B                  |                                 |
| 12. Human Papilloma Virus        |                                 |
| 13. Influenza                    |                                 |
| 14. Japanese Encephalitis        |                                 |
| 15. Meningococcal                |                                 |
| 16. Pneumococcal                 |                                 |
| 17. Poliomyelitis                |                                 |

Inactivated vaccines	Live-attenuated vaccines	mRNA   pDNA vaccines	Subunit, recombinant, polysaccharide, and conjugate vaccines	Toxoid vaccines	Viral vector vaccines
Hep A Influenza (Injectable only) Polio (Injectable only) Rabies	Chickenpox Chikungunya Influenza Japanese Encephalitis MMR Smallpox Yellow fever	COVID-19	Hib Hep B HPV Pertussis (Tdap) Pneumococcal Meningococcal Shingles (Herpes Zoster)	Diphtheria Tetanus	COVID-19

# Anthrax

<b>Vaccine type:</b> Cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of <i>Bacillus anthracis</i> . Live Attenuated Vaccine											
<b>Route of administration:</b> Intramuscular (IM) for preexposure   Subcutaneous (SC) for postexposure											
<b>Dose:</b> 0.5 mL   0, 1, and 6 months   Booster if risk persists: 6 months after primary dose series											
<b>Storage:</b> 2°C – 8°C											
<b>Guideline recommendations for Anthrax Vaccine in adults</b>											
<b>API</b> <sup>6</sup>	<b>RSSDI</b> <sup>7</sup>	<b>ISN</b> <sup>8</sup>	<b>GSI</b> <sup>9</sup>	<b>IMA</b> <sup>10</sup>	<b>FOGSI</b> <sup>11,12</sup>	<b>NHM</b> <sup>13</sup>	<b>CDC</b> <sup>14,15</sup>				
-	-	-	-	-	-	-	People at increased risk of exposure or have been exposed				
<b>Indian Consensus Recommendations:</b>											
Age ≥50 yrs	<b>Age 18 - 49 years</b>										
	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>NR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- Not recommended for general use, should only be used in people at increased risk of exposure or in people who have been exposed
  - Livestock handlers in endemic areas
  - Laboratory workers at risk of exposure
- Pre-exposure prophylaxis for adults aged 18–65 years at high risk for exposure, intramuscularly (IM) at 0, 1, and 6 mo. with boosters at 6 and 12 mo. after completion of the primary series and at 12-month intervals thereafter if the risk persists
- Post-exposure prophylaxis in combination with antimicrobials for adults aged 18–65 years with suspected or known exposure subcutaneously (SC) at 0, 2, and 4 weeks

# Chickenpox

<b>Vaccine type:</b> Live attenuated											
<b>Route of administration:</b> Subcutaneous (SC)											
<b>Dose:</b> 2 doses 0.5 ml at least 4-6 weeks apart											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Guideline recommendations for Chickenpox vaccines in adults</b>											
<b>API<sup>6</sup></b>	<b>RSSDI<sup>7</sup></b>	<b>ISN<sup>8</sup></b>	<b>GSI<sup>9</sup></b>	<b>IMA<sup>10</sup></b>	<b>FOGSI<sup>11,12</sup></b>	<b>NHM<sup>13</sup></b>	<b>CDC<sup>14</sup></b>				
At risk -OR- No evidence of immunity	At risk	Recommended	At risk	If no evidence of immunity	Preconception or not recommended during pregnancy	At risk	At risk				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>NR</b>	<b>NR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- Routinely recommended in adults without evidence of immunity
- Recommended in adults who are at potential risk of exposure such as Individuals or students residing in hostel, HCPs and household contacts
- Post-exposure vaccination: Recommended within a few days to a few weeks of exposure.
  - Incomplete vaccination: One dose
  - Not-vaccinated: Two doses

# Chikungunya

On the 9<sup>th</sup> of November '23, USFDA approved the first chikungunya vaccine, for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus; following two clinical studies conducted in North America in which about 3,500 participants 18 years of age and older received a dose of the vaccine with one study including about 1,000 participants who received a placebo.<sup>16</sup>

<b>Vaccine type:</b> Live attenuated											
<b>Route of administration:</b> Intramuscular injection (IM)											
<b>Dose:</b> 0.5 mL   1 dose											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Contraindication:</b> History of allergic reaction to any component of the vaccine, immunodeficient or Immunosuppressed due to disease or medical therapy (e.g., from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised).											
<b>Guideline recommendations for Chikungunya vaccines in adults</b>											
<b>API<sup>6</sup></b>	<b>RSSDI<sup>7</sup></b>	<b>ISN<sup>8</sup></b>	<b>GSI<sup>9</sup></b>	<b>IMA<sup>10</sup></b>	<b>FOGSI<sup>11,12</sup></b>	<b>NHM<sup>13</sup></b>	<b>CDC<sup>14</sup></b>				
-	-	-	-	-	-	-	-				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
<b>Age ≥50 yrs</b>	<b>Pregnancy</b>	<b>Immuno-compromised</b>	<b>HIV infection</b>	<b>Asplenia, complement deficiencies</b>	<b>CKD  HD</b>	<b>Heart  lung disease</b>	<b>CLD  alcoholism</b>	<b>DM</b>	<b>HCP</b>	<b>Traveller</b>	<b>Mass gathering</b>
<b>R</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>R</b>	<b>BR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- For individuals 18 year or older at increased risk of exposure to chikungunya virus

\*\*Not yet approved | available for clinical use in India\*\*

## Cholera

	<b>Killed Whole-Cell Monovalent (01) Vaccine with a Recombinant Cholera Toxin B Subunit WC-rBS</b>	<b>Killed Whole-Cell Bivalent (01 and 0139) Vaccine without the Cholera Toxin B Subunit BivWC</b>	<b>Killed Whole-Cell Bivalent (01 and 0139 without Cholera Toxin B Subunit) BivWC</b>	<b>Live Attenuated Vaccine CVD 103-HgR</b>
Route of administration	Oral	Oral	Oral	Oral
Recommended age of vaccination	2 doses in adults and children $\geq 6$ years of age, 3 doses for children aged $< 6$ years; $\geq 1$ week before potential exposure 2 doses in adults and children $\geq 6$ years of age, 3 doses for children aged $< 6$ years; $\geq 1$ week before potential exposure	2 doses at an interval of 2 weeks; earliest onset of protection 7–10 days after completion	2 doses at an interval of 2 weeks	Single dose; $\geq 10$ days before potential exposure
Recommended age of vaccination	Adults and children $\geq 2$ years of age	Adults and children $\geq 1$ year of age	Adults and children $\geq 1$ year of age	Adults and children aged $\geq 6$ years

# Cholera

<b>Route of administration:</b> Oral											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Guideline recommendations for Cholera vaccine in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>			CDC <sup>14</sup>		
18–65 years (1 dose if traveling to an endemic region)	-	2 doses 1-6 weeks apart	-	At risk (2 doses)	-	All age groups (In a resource-limited set up prioritize high-risk group)			18–65 years (1 dose if traveling to an endemic region)		
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>BR</b>	<b>R</b>	<b>R</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- Routine administration is not recommended
- Recommended as 2 doses, at least 2 weeks apart only in:
  - Travelers
  - Potential exposure to cholera patients
  - Exposure to contaminated water and food, particularly those staying in areas with limited access to health care facilities
  - During natural calamity
  - During endemic/outbreak

## Corona Virus Disease 2019 (COVID-19)

### List of COVID-19 Vaccines Approved by CDSCO in India<sup>17</sup>

Vaccine	Age group and dosing schedule	Route & storage
ChAdOx1 nCoV-19 Corona Virus vaccine (Recombinant) (COVISHIELD)	For ≥18 years age Two doses, 4 to 6 weeks apart (Overseas Data available for 12 weeks)	Intramuscular, 2-8°C
Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN)	For ≥18 years age Two doses, Day 0 & 28	Intramuscular, 2-8°C
Gam COVID Vac (component I & II) (SPUTNIK-V)	For ≥18 years age Two doses, Day 0 (comp I) & Day 21 (comp II)	Intramuscular, -18°C
mRNA-1273COVID-19 vaccine (Moderna vaccine)	For ≥18 years age Two doses, Day 0 & 28	Intramuscular, -25°C to -15°C
COVID-19 vaccine (Ad26.COVS-2-S) [recombinant] (Janssen Vaccine)	For ≥18 years age Single dose	Intramuscular, -25°C to -15°C & 2-8°C
Novel Corona Virus-2019-nCov vaccine (recombinant DNA) (ZyCoV-D)	For ≥12 years age Three doses (Day 0, 28 and 56)	Intradermal, 2-8°C
Gam COVID Vac (component I & II) (SPUTNIK-V)	For ≥18 years age Two doses, Day 0 (comp I) & Day 21 (comp II)	Intramuscular, -18°C
Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN)	For 12 to 18 years age Two doses, Day 0 & 28	Intramuscular, 2-8°C
	>6 to <12 years Two doses, Day 0 & 28	
SARS-CoV-2 vaccine containing Receptor Binding Domain (RBD) of SARS-CoV-2 gene (CORBEVAX)	For ≥18 years age Two doses, Day 0 & 28	Intramuscular, 2-8°C
	For ≥12 years age Two doses, Day 0 & 28	
	>5 to <12 years – Two doses, Day 0 & 28	
SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine [COVOVAX]	For ≥18 years age Two doses, Day 0 & 21	Intramuscular, 2-8°C
	For ≥12 years age Two doses, Day 0 & 21	
Recombinant adenoviral vector vaccine containing particles of S gene of the SARS-CoV-2 virus (SPUTNIK Light)	For ≥18 years age Single dose	Intramuscular, -18°C
Lyophilized mRNA Vaccine for Injection (COVID-19) [HGCO-19]	For ≥18 years of age Two doses, Day 0 & 28	Intramuscular, 2-8°C
BBV154 - Adenovirus vectored, intranasal vaccine (iNCOVACC)	For ≥18 years of age	Intranasal

## Corona Virus Disease 2019 (COVID-19)

Guideline recommendations for COVID-19 vaccines in adults											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
2-dose series followed by booster in special situations	-	At risk (2 doses)	-	-	2-dose series even during pregnancy	2-dose series followed by booster in special situations	2 or 3 dose series followed by booster in special situations				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

### Key considerations:

- At the time of pandemic or local epidemic situations: Routine administration is strongly recommended for all, even during pregnancy – 2 doses – at least 4 weeks apart
- Additional booster doses: for all older adults and adults with significant comorbidities or severe obesity (high priority-use group) – At least 12 mo. after the previous dose

#### Note:

- The recommendations for use are limited to pandemic or local epidemic situations only. Please refer to the latest government recommendations for the frequency of repeat| booster doses.
- There are no head-to-head to head studies comparing the different vaccines available for the prevention of COVID-19, please check local availability and the most recent government notification for the selection of vaccine.

## Diphtheria, Pertussis and Tetanus (Tdap)

**Vaccine type:** Tdap: Diphtheria and tetanus toxoids and acellular pertussis antigens | Td: Diphtheria (reduced dose) and tetanus toxoids

**Route of administration:** Intramuscular injection (IM)

**Dose:** 0.5 ml | 1 dose 10 yearly

**Storage:** Should be stored between 2°C and 8°C.

**Contraindication:** History of allergic reaction

### Guideline recommendations for Tdap vaccines in adults

API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>
If not vaccinated immediately, then every 10 years	Recommended	<p>1. If not vaccinated, 3 doses of Td at 0,1 and 6-12 mo. apart, Tdap can be used as one of the doses, then every 10 yrs.</p> <p>2. For age ≥65 yrs administer the first dose of Tdap followed by Td every 10 yrs.</p>	Tdap for all adults aged 65 years and older	If not vaccinated immediately, then every 10 years	Pre-conceptual period if at risk Tdap during pregnancy	If not vaccinated immediately, then every 10 years. During pregnancy 2 doses of TT	If not vaccinated immediately, then every 10 years

### Indian Consensus Recommendations:

Vaccine	Age ≥50 yrs	Age 18 - 49 years										
		Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
Td	R	BR	R	R	R	R	R	R	R	R	R	R
Tdap	BR	R	BR	BR	BR	BR	BR	BR	BR	BR	BR	R

**R:** Recommended | **NR:** Not recommended | **BR:** May be considered after benefit risk evaluation | **AR:** With additional risk | **CKD:** Chronic kidney disease | **HD:** Haemodialysis | **DM:** Diabetes mellitus | **CLD:** Chronic liver disease | **HCP:** Health care personnel | **CV:** Cardiovascular | **ICU:** Intensive care unit

## Key considerations:

- Un-vaccinated: 1 dose of Tdap, then 1 dose of Td or Tdap 4 weeks later, and a third dose of Td or Tdap 6–12 mo. later (Tdap preferred as the first dose), with Td or Tdap every 10 years thereafter.
- During each pregnancy, it is recommended to receive one dose of Tdap, preferably between the gestational weeks of 27 and 36.
- Wound management: 3+ doses of tetanus-toxoid vaccine - Tdap|Td if >10 years since last dose for clean|minor wounds, >5 years for other wounds. Prefer Tdap for those without previous Tdap history.

## Haemophilus influenzae type b (Hib) infection

**Vaccine type:** Lyophilized killed | Conjugate Vaccine (capsular polysaccharide bound to carrier protein)  
Available as: Pentavalent|bivalent combination or hexavalent injection

**Route of administration:** Intramuscular injection (IM)

**Dose:** 0.5 ml | 1 dose | For HSCT Recipients 3 doses at least 4 weeks apart

**Storage:** Should be stored between 2°C and 8°C.

### Guideline recommendations for Hib vaccines in adults

API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>
At risk* (1 or 3 doses)	-	At risk* (1 dose)	-	At risk* (1 or 3 doses)	-	Not recommended	At risk* (1 or 3 doses)

\***At Risk:** asplenia, HIV, hematological malignancies, corticosteroid use, CSF leak, trauma, diabetes, pregnancy, alcoholism, immunosuppression due to bone marrow or kidney transplant, cancer, radiation, or chemotherapy should be vaccinated.

### Indian Consensus Recommendations:

Age ≥50 yrs	Age 18 - 49 years										
	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>R</b>	-	<b>R</b> (3 doses for HSCT)	<b>AR</b>	<b>AR</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>

**R:** Recommended | **NR:** Not recommended | **BR:** May be considered after benefit risk evaluation | **AR:** With additional risk | **CKD:** Chronic kidney disease | **HD:** Haemodialysis | **DM:** Diabetes mellitus | **CLD:** Chronic liver disease | **HCP:** Health care personnel | **CV:** Cardiovascular | **ICU:** Intensive care unit

## Key considerations:

- Vaccination is a part of primary immunization
- Adults at high risk such as patients with immunocompromised state, CSF leak, trauma, diabetes, pregnancy, alcoholism, cancer, radiation, or chemotherapy: 1 dose
- Elective splenectomy If unvaccinated: 1 dose (at least 14 days before splenectomy)
- Functional or anatomic asplenia If unvaccinated: 1 dose
- HSCT Recipients: 3 doses at least 4-week intervals; 6–12 mo. after transplant, regardless of Hib vaccine history

# Hepatitis A

## Available vaccines and relevant population to receive them.

Protects against	Dosing schedule	Relevant populations
HepA-HepB	3 doses 0, 1 month	Age 19 years and above
Vaccine	& 3-6 month	At Risk of Infection

**Vaccine type:** Inactivated vaccine

**Route of administration:** Intramuscular injection (IM)

**Dose:** 0.5 ml | 2 doses, 6 months apart

**Storage:** Should be stored between 2°C and 8°C.

Contraindicated during pregnancy

### Guideline recommendations for HepA vaccines in adults

API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>
At risk* (2 doses, 6 mo. apart)	Recommended	At risk* (2 doses, 6 mo. apart)	-	Adults (1 dose of live or 2 doses of inactivated at 0 & 6 mo.)	-	Not recommended	At risk* (1 or 3 doses)

**\*At Risk:** Chronic liver disease (e.g., persons with hepatitis B, hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal), Undergoing liver transplant, HIV infection, Men who have sex with men, Injection or non-injection drug use, Homeless individuals homelessness, During pregnancy, if at risk of infection or worse outcome, Increased risk of exposure eg:healthcare setup,drug abuse or residential group facilities. Work with hepatitis A virus in research laboratory or with non-human primates with hepatitis A virus infection

# Hepatitis A

Indian Consensus Recommendations:											
Age ≥50 yrs	Age 18 - 49 years										
	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>R</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>R</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>NR</b>

**R:** Recommended | **NR:** Not recommended | **BR:** May be considered after benefit risk evaluation | **AR:** With additional risk | **CKD:** Chronic kidney disease | **HD:** Haemodialysis | **DM:** Diabetes mellitus | **CLD:** Chronic liver disease | **HCP:** Health care personnel | **CV:** Cardiovascular | **ICU:** Intensive care unit

## Key considerations:

- Any person who is not fully vaccinated & who is at risk for hepatitis A virus infection 2-dose series Hep A or 3-dose series Hep A-Hep B as above.
- At risk for hepatitis A virus infection: 2-dose series HepA 6–18 mo. apart or 3-dose series HepA-HepB (0, 1, 6 mo. [minimum intervals: dose 1 to dose 2: 4 weeks | dose 2 to dose 3 – 6 mo.])
- Travel in countries with high or intermediate endemic hepatitis A (HepA-HepB may be administered on an accelerated schedule of 3 doses at 0, 7, and 21–30 days, followed by a booster dose at 12 mo.)
- Booster dose if required, should be given at any time between 6 mo. and 5 years, but preferably between 6 and 12 mo.

# Hepatitis B

<b>Vaccine type:</b> Recombinant DNA or plasma-derived inactivated subunit vaccine											
<b>Route of administration:</b> Deep Intramuscular injection (IM) in the Deltoid region; avoid buttocks											
<b>Dose:</b> 1 ml   3 doses at 0, 1, 6 months											
<b>Storage:</b> Stored between 2°C and 8°C.											
<b>Note:</b> Revaccination is recommended every 5 years for high-risk individuals (Immunocompromised, HCPs, CKD on hemodialysis etc.)											
<b>Contraindication:</b> History of allergic reaction   allergic reaction Baker's yeast											
<b>Guideline recommendations for HepB vaccines in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
At risk* (3 doses at 0, 1 & 6 mo.) Revaccinate on every 5 years	For 19-59 years 3 dose series is recommended; for ≥60 years 3 dose series can be considered	At risk* (3 doses)	-	Adults (3 doses at 0, 1 & 6 mo.)	Preconception or at high risk during pregnancy	At risk* -OR- seeking protection (including post-exposure prophylaxis)	At risk* (2, 3, or 4 doses depending on the type of vaccine)				
<p><b>*At Risk:</b></p> <ul style="list-style-type: none"> <li>Chronic liver disease (e.g., persons with hepatitis C, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)</li> <li>HIV infection</li> <li>Men who have sex with men</li> <li>Injection or non-injection drug use</li> </ul>											
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>AR</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>NR</b>
<p><b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit</p>											

## Key considerations:

- At risk for hepatitis B virus infection: 3-dose series HepB (0, 1, 6 mo. [minimum intervals: dose 1 to dose 2: 4 weeks | dose 2 to dose 3 – 6 mo.])
- Travel in countries with high or intermediate endemic hepatitis A (HepA+HepB may be administered on an accelerated schedule of 3 doses at 0, 7, and 21-30 days, followed by a booster dose at 12 mo.)

# Human Papilloma Virus

<b>Vaccine type:</b> Recombinant protein capsid liquid vaccine											
<b>Vaccines available in India:</b> Bivalent (HPV2) protects against HPV 16 and 18   Quadrivalent (HPV4) protects against HPV 6,11, 16 and 18   Nonavalent (HPV9) protects against HPV 6,11											
<b>Route of administration:</b> Intramuscular injection (IM)											
<b>Dose:</b> 1 ml   2 or 3 doses at 0, 1 & 6 months											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Note:</b> There is currently no recommendation for HPV use in pregnancy. Consider delaying HPV until after pregnancy											
<b>Guideline recommendations for HPV vaccines in adults</b>											
<b>API<sup>6</sup></b>	<b>RSSDI<sup>7</sup></b>	<b>ISN<sup>8</sup></b>	<b>GSI<sup>9</sup></b>	<b>IMA<sup>10</sup></b>	<b>FOGSI<sup>11,12</sup></b>	<b>NHM<sup>13</sup></b>	<b>CDC<sup>14</sup></b>				
Women ≤26 years (3 doses); men ≤21 years (3 doses)	Can be considered	9–14 years: 2 doses 6 mo. apart >15 years, 3 doses at 0, 1, and 6 mo.	-	Females 9–14 years: 2 doses 0, 6 mo.; 15–45 years: 3 doses (0, 1-2 & 6 mo.)	9–26 years; next dose(s), Delay after pregnancy	Females before the onset of sexual activity (3 doses)	Age ≥15 yrs.: 3-doses at 0, 1-2 mo., 6 mo.)				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 45 years</b>											
Age ≥46 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
	<b>NR</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>NR</b>	<b>NR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- Before the first sexual encounter
- HPV vaccination is advised for all people up to age 26: Depending on the age at the first immunization or the condition, a 2- or 3-dose series:
  - Age 15 or older at the time of the initial vaccination: 3-dosage series given over the course of 0, 1, and 6 mo. (minimum intervals: 4 weeks between doses 1 and 2, 12 weeks between doses 2 and 3, and 5 mo. between doses 1 and 3; repeat dose if given too soon).
  - Age 9 to 14 years at the time of the initial vaccination and 1 or 2 doses given no more than 5 mo. apart: 1 extra dosage -Aged 9 to 14 at the time of the first vaccination and 2 doses received at least 5 mo. apart: Complete HPV vaccine series; no further dose is required
- Adults age 27–45 years: Based on shared clinical decision-making, 2- or 3-dose series as above
- Immunocompromising diseases: Such as HIV infection: 3-dose series, even for those who start immunization at age 9 to 14

\*\*All above recommendations are for females <45 years of age and before the first sexual encounter\*\*

# Influenza

## Vaccine type:

- Inactivated Influenza Vaccine (IIV) includes recombinant trivalent and quadrivalent influenza vaccines. Intra Muscularly route
- Live attenuated influenza vaccine (LAIV). Intranasal Route

**Dose:** 0.5 ml | 1 dose | Annually

## Coadministration:

If 2 or more of the following live virus vaccines are to be given – LAIV, MMR, Var, and/or yellow fever they should be given on the same day. If they are not given on the same day, space them by at least 28 d (30 d for yellow fever). Other inactivated and subunit e.g., PCV13, Shingles (Herpes Zoster) etc. can be added as needed| indicated.

## Contraindications for LAIV:

Age ≥50yrs, pregnant women, history of allergic reaction to any excipients of the vaccine or eggs, immunocompromised, received antiviral therapy in ≤48hrs, caregivers of immunocompromised patients requiring isolated environment, patients with asthma, Guillain Barre Syndrome, chronic conditions, etc.

## Guidelines Recommending the Influenza Vaccine

API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>
Yearly (1 dose); Also, during pregnancy (IIV)	Yearly (1 dose)	1 dose Yearly for at risk, including during pregnancy (IIV)	Routinely once a year	Yearly, at risk, including during pregnancy (IIV)	At risk, including during pregnancy (IIV)	Not recommended	Yearly (1 dose); during pregnancy (1 dose)

## Indian Consensus Recommendations:

Vaccine	Age ≥50 yrs	Age 18 - 49 years											
		Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering	
IIV RIV	R	R	R	R	R	R	R	R	R	R	R	R	R
LAIV	NR	NR	NR	NR	NR	BR	BR	BR	BR	R	R	R	R

**R:** Recommended | **NR:** Not recommended | **BR:** May be considered after benefit risk evaluation | **AR:** With additional risk | **CKD:** Chronic kidney disease | **HD:** Haemodialysis | **DM:** Diabetes mellitus | **CLD:** Chronic liver disease | **HCP:** Health care personnel | **CV:** Cardiovascular | **ICU:** Intensive care unit

## Key considerations:

- Adults who have not received the vaccine should continue to receive it throughout the entire influenza season, especially during times when the virus is active in the neighbourhood e.g. should be given before winter in northern states such as J & K and Delhi while should be given before monsoon for rest of India.
- All adults, including pregnant women: 1 dose annually
  - All adults: IIV or RIV4 -OR- • For adults up ≤49 yrs age: LAIV

**Note:** Close contacts and caregivers who care for severely immunocompromised persons (i.e., those who require care in a protective environment) should receive IIV, cIIV, or RIV rather than LAIV.

At the time of preparing these guidelines trivalent influenza vaccine is not available in India, if and when available trivalent vaccine should be preferred over tetravalent vaccine, as B/Yamagata strains have not been found in India since March 2020. Although there has been co-circulation of two influenza B virus lineages in past, B/Yamagata-lineage circulation has not been verified since March 2020. The use of quadrivalent live-attenuated vaccines may lead to its detections. All type B viruses identified after March 2020 have been linked to the B/Victoria lineage. A global effort is required to identify the lineage of type B influenza viruses in order to determine whether or not B/Yamagata-lineage viruses are extinct

# Japanese Encephalitis

<b>Vaccine type:</b> Live attenuated											
<b>Route of administration:</b> subcutaneous injection (SC)											
<b>Dose:</b> 0.5 ml   Inactivated vaccine: 2 doses at least 4-week apart											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Contraindication:</b> Pregnancy <b>Note:</b> Live vaccine should not be given during epidemic season											
<b>Guideline recommendations for JE vaccines in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
-	-	-	-	One dose, Delay pregnancy by 3 mo., Live vaccine should not be given during epidemic season	-	Not recommended	Inactivated vaccine: 2 doses at 4-week gap starting the primary series at ≥6 months of age in endemic settings <sup>23</sup>  For immunocompromised individuals, Healthcare workers and Migrants to JE endemic area.				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥46 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>AR</b>	<b>R</b>	<b>BR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- Vaccination is recommended for travelers who plan to stay in endemic areas for a month or longer during the transmission season, even if they stay primarily in urban areas.
- For short-term travelers (less than a month), vaccination should be considered if they plan to spend long periods outdoors in rural or agricultural areas, engage in outdoor activities, or be in areas without adequate protection such as air conditioning, screens, etc. or mosquito nets.
- It should also be considered for travelers visiting areas with ongoing outbreaks or uncertain travel destinations, activities and travel duration.
- However, vaccination is not currently recommended for short-term travelers whose plans relate exclusively to urban areas.
- Can be administered during Kumbh Melas if stay is longer than 1 month.
- Patients with chronic illness or immunodeficiency who live in or move to endemic areas.
- Pregnant women traveling or staying in endemic areas always weigh the benefit-risk ratio before administration

# Measles, Mumps and Rubella

<b>Vaccine type:</b> Live-attenuated combined vaccine											
<b>Available Combinations:</b> MR= Measles & Rubella   MMR= Measles, Mumps & Rubella   MMRV= Measles, Mumps, Rubella & Varicella											
<b>Route of administration:</b> subcutaneous injection (SC)											
<b>Dose:</b> 0.5 ml   2 doses 4 weeks apart											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Precautions</b>											
<ul style="list-style-type: none"> <li>• Moderate or severe acute illness with or without fever.</li> <li>• If blood, plasma, and/or immune globulin were given in past 11 mo., wait for 3 mo. before vaccinating.</li> <li>• History of thrombocytopenia or thrombocytopenic purpura.</li> </ul>											
<b>Note:</b> The MMR vaccine is not advised if the patient is pregnant because it is a live attenuated vaccine and could potentially harm the foetus. But in case a pregnant woman receives the MMR, the pregnancy should NOT be terminated on that basis since, there is no proof that the MMR or MMRV vaccines pose a teratogenic risk. Pregnant women may receive the MMR vaccine during measles or rubella outbreaks since the possible advantages of vaccination outweigh the dangers. Since the MMR vaccine is safe during breastfeeding, non-immunized patients should receive it after delivery.											
<b>Co-administration:</b> If 2 or more of the following live virus vaccines are to be given – MMR, LAIV, Var, and/or yellow fever – they should be given on the same day. If they are not given on the same day, space them by at least 28 d (30 d for yellow fever). May use as post-exposure prophylaxis if given within 3 d of exposure.											
<b>Guideline recommendations for MMR vaccines in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>				CDC <sup>14</sup>	
26–55 years (2 doses 28 days apart)	-	Unimmunized (1 dose)	-	2 doses 4-8 weeks apart, if previously immunised 1 dose	MMR for routine preconception  postnatal (pregnancy should be deferred for 3 mo.)	2 doses of Rubella vaccine - HCPs; in the setting of outbreaks; recent exposure to these infections   women in child bearing age; and college students.				19–59 years (1 or 2 doses)	
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>R</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>R</b>	<b>NR</b>	<b>NR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- Is part of routine vaccination
- If unvaccinated: 2 doses at least 4 weeks apart
- If woman of childbearing-age is found to be rubella susceptible and is not pregnant, give 1 dose of MMR; if she is pregnant, the dose should be given postpartum

# Meningococcal disease

<b>Vaccine type:</b> Purified bacterial capsular polysaccharide (PBCP)   Conjugate Vaccine													
<b>Route of administration:</b> PBCP Subcutaneous   Conjugate vaccine intramuscular injection (IM)													
<b>Dose:</b> 0.5 ml   1 dose													
<b>Storage:</b> Should be stored between 2°C and 8°C.													
<b>Guideline recommendations for Meningococcal vaccines in adults</b>													
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>						
At risk* (Immunocompromised individuals, high-risk travelers and mass gatherings): 1 dose	-	High risk Travelers and epidemic <16 years: 2 doses >16 years: Single dose	-	Adults (1 dose); At risk* (2 doses 4 weeks apart)	-	Not recommended	Adolescent or Travelers to high risk countries: 1 dose At risk* 2 dose series, at least 8 weeks apart, booster every 5 years if risk continues						
*At Risk: International travelers, Men who have sex with men, People who use or inject drugs (all those who use illegal drugs), People with occupational risk for exposure, People who anticipate close personal contact with an international adoptee, People experiencing homelessness, People with CLD & People with HIV													
<b>Indian Consensus Recommendations:</b>													
Vaccine	Age ≥50 yrs	Age 18 - 49 years											
		Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering	
<b>Men ACWY</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>R</b>	<b>R</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>R</b>	<b>R</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit													

## Key considerations:

- Dose 0.5cc Subcutaneous injection given in 1 dose in most adults
- Anatomical or functional asplenia (including sickle cell disease), HIV infection, persistent complement component deficiency, complement inhibitor (e.g., eculizumab, ravulizumab): 2-dose at least 8 weeks apart and revaccinate every 5 years if risk remains
- Travel to countries with hyperendemic or epidemic meningococcal disease, or mass gatherings, or microbiologists routinely exposed to *Neisseria meningitidis*: 1 dose and revaccinate every 5 years if risk remains
- First-year college students who live in residential housing (if not previously vaccinated at age 16 years or older) or military camps: 1 dose
- It is recommended only up to the age 55 years

# Pneumococcal Disease

## Vaccine type:

- **Pneumococcal Polysaccharide Vaccine (PPSV23):**  
It provides protection against 23 serotypes of Streptococcus pneumoniae serotypes viz.; 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F.
- **Pneumococcal Conjugate Vaccine 13 (PCV13):** PCV13 provides protection against 13 serotypes of S. pneumoniae viz.; 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
- **Pneumococcal Conjugate Vaccine 15 (PCV15):** PCV15 provides protection against 15 serotypes of S. pneumoniae viz.; 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.
- **Pneumococcal Conjugate Vaccine 20 (PCV20):** PCV20 provides protection against 20 serotypes of S. pneumoniae viz.; s 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

## Note:

According to research by Greenberg et al. among treatment-naive individuals an initial single dose of PCV13 increases the anti-pneumococcal response to subsequent administration of PPSV23 for several common vaccine serotypes. This happens because the conjugated PCV13 vaccination, when given sequentially with PPSV23, recalls and enhances the immune response. On the other hand, following administration of PCV13 for all serotypes results in a reduced response when PPSV23 is first administered before PCV13. The study assisted in offering a plausible justification for the advice to administer PCV13 first and PPSV23 later.<sup>19</sup>

\*\*PCV15 and PCV20 are currently not registered | available in India\*\*

**Route of administration:** PPSV23: Intramuscular or subcutaneous injection | PCV13: intramuscular injection

**Dose:** PCV13- 0.5ml | PPSV23- 0.5ml | 1 dose of PCV13 followed by PPSV23 1 year later

**Storage:** Should be stored between 2°C and 8°C.

**Co-administration:** Adults can receive pneumococcal vaccines (any PCV13 or PPSV23) with herpes zoster vaccines, seasonal influenza vaccines etc. at the same time if required on different arms.

## Guideline recommendations for Pneumococcal vaccines in adults

API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	ICS <sup>20</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>
<p>≥19 years (Chronic conditions, Immunocompromised): 1 dose PCV13 followed by PPSV23 8 weeks later.</p> <p>≥50 years: 1 dose PCV13 followed by PPSV23 (1 year later)</p>	<p>≥50 years: 1 dose PCV13 followed by PPSV23 (1 year later) Booster: if needed ≥5 years after previous PPSV23 dose</p>	<p>≥19 years: Single dose of PCV13 first followed by PPSV23 after 8 weeks. Administer 1 dose of PPSV23 ≥5 years later.</p>	<p>For &gt;50 years PCV13 followed by PPSV23 (one year gap) PCV13 is recommended in all adults &gt; 50 years</p>	<p>1 dose of PCV13 followed by 1 dose of PPSV23 at least 8 weeks</p> <p>2 doses PPSV23 at least 5 years apart</p>	<p><b>Adults ≥19 years with chronic conditions and Immunocompromised conditions:</b> A single dose of PCV13 followed by PPSV23 ≥ 8 weeks later is recommended</p>	<p>Not routinely recommended</p>	<p>Not previously received a dose of PCV13, PCV15, or PCV20 or whose previous vaccination history is unknown: 1 dose PCV15 OR 1 dose PCV20.</p> <p>If PCV15 is used, administer 1 dose PPSV23 at least 1 year after the PCV15 dose (may use minimum interval of 8 weeks for adults with an immunocompromising condition).</p>

# Pneumococcal Disease

Indian Consensus Recommendations:											
Age ≥50 yrs	Age 18 - 49 years										
	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>R</b>	-	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>R</b>	<b>AR</b>	<b>R</b>	<b>R</b>

**R:** Recommended | **NR:** Not recommended | **BR:** May be considered after benefit risk evaluation | **AR:** With additional risk | **CKD:** Chronic kidney disease | **HD:** Haemodialysis | **DM:** Diabetes mellitus | **CLD:** Chronic liver disease | **HCP:** Health care personnel | **CV:** Cardiovascular | **ICU:** Intensive care unit

## Key considerations:

- Recommended for all, especially those with increased risk irrespective of age (for adults) 1 dose of PCV13 followed by PPSV23 1 year later
- Above 50 years: PCV 13 followed by PPSV23, 1 year later
- At-risk or Age >50 years :1 dose PCV13 Followed by 1 dose of PPSV23 atleast 1 year later and second dose of PPSV23 atleast 5 years later.
- High-risk:1 dose of PCV13 followed by 1 dose of PPSV23 atleast 8 weeks later and second dose of PPSV23 atleast 5 years later.
- PCV15 and PCV20 are recommended for adults (Once Approved & Available)
  - Above 50 years: 1 dose of PCV20 only, OR PCV 15 followed by PPSV23 1 year later
  - At-risk: 1 dose of PCV20 only, OR PCV 15 followed by PPSV23 1 year later
  - High-risk: 1 dose of PCV20 only, OR PCV 15 followed by PPSV23 8 weeks later

# Poliomyelitis

<b>Vaccine type:</b> Live Attenuated (OPV)   Inactivated Polio Vaccine (IPV)											
<b>Route of administration:</b> OPV Oral   IPV intramuscular injection (IM)											
<b>Dose:</b> IPV 0.5 ml   <b>OPV:</b> 2 drops   3 doses 0, 1 and 6-12 months											
<b>Storage:</b> <b>IPV:</b> Should be stored between 2°C and 8°C <b>OPV:</b> Highly heat sensitive and should be kept frozen during storage (after thawing it can be kept between 2 °C and 8 °C for up to 6 mo.)											
<b>Contraindication:</b> Pregnancy											
<b>Guideline recommendations for Polio vaccines in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
IPV: 3 doses (6, 10-14 weeks)->2mo. of age IPV-bOPV schedule-1 or 2 doses of IPV followed by ≥2 doses of bOPV	Recommended	Unimmunized: 3 doses of IPV OPV spaced by 1 month Immunized: Single dose of IPV	-	2 doses of IPV	-	Not routinely recommended	At risk* (3 doses 0, 1-2 & 6-12 mo.)				
<p><b>*At Risk:</b> Travelers who are going to countries where polio is an epidemic or endemic (For additional information, see Polio: For Travelers), Laboratory and healthcare workers who handle specimens that might contain polioviruses, Healthcare workers or other caregivers who have close contact with a person who could be infected with poliovirus, Adults who are identified by public health authorities as being part of a group or population at increased risk of exposure because of an outbreak.</p>											
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>BR</b>	<b>R</b>	<b>NR</b>
<p><b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit</p>											

## Key considerations:

- Previously vaccinated: one lifetime booster dose of IPV
  - Travelers to countries where polio is an epidemic or is endemic.
  - Laboratory and healthcare workers who handle specimens that might contain polioviruses.
  - Healthcare workers or other caregivers who have close contact with a person who could be infected with poliovirus.
- Unvaccinated or incompletely vaccinated adults: 3 doses
  - First dose at any time, followed by second dose at least 1 month later & third dose 6-12 mo. after second dose

# Rabies

## Categories of contact with suspect rabid animal<sup>21</sup>

**Category I** - Touching or feeding animals, animal licks on intact skin (no exposure)

**Category II** - nibbling of uncovered skin, minor scratches or abrasions without bleeding (exposure)

**Category III** - single or multiple transdermal bites or scratches, contamination of mucous membrane or broken skin with saliva from animal licks, exposures due to direct contact with bats (severe exposure)

<b>Vaccine type:</b> Concentrated, purified cell culture & embryonated egg-based vaccine											
<b>Available as:</b> Human diploid cell vaccine   Purified chick embryo cell vaccine   Purified duck embryo cell vaccine   Purified Vero cell rabies vaccine											
<b>Route of administration:</b> Intramuscular injection (IM)   Intradermal injection (for resource limited setup e.g., government hospitals receiving several at risk patients in a day)											
<b>Dose:</b> 0.5 ml PVRV   1 ml HDCV or PCEC or PDEC											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Contraindication:</b> History of allergic reaction   Egg allergy   pregnancy & lactation   Immunocompromised											
<b>Guideline recommendations for Rabies vaccines in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
Pre-exposure: 3 doses (0, 7, 28 days for high-risk groups) Postexposure: 5 doses (0, 3, 7, 14, and 28 days)	-	Pre-exposure: 3 doses (0,7, and 28 days) Postexposure: 5 doses (0,3, 7, 14 and 28 days)	Post-exposure (5 doses at day 0,3,7,14 and 28)	Pre-exposure (3 doses- 0,7 & 28 days) Post-exposure (4 doses- 0, 3, 7 & 14 28 days)	-	-	At risk* (1 or 3 doses)				
<b>Indian Consensus Recommendations:</b>											
Age ≥50 yrs	Age 18 - 49 years										
	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>R</b> (5Dose)	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>BR</b>	<b>R</b>	<b>NR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- Pre-exposure high risk
  - Work as a veterinarian or animal handler
  - Are a veterinary student
  - Study or explore caves
  - Study the rabies virus
  - Are traveling to other countries where rabies is common
  - Joggers, walkers and pet owners should be encouraged
- For pre-exposure 3 doses at 0, 7 & 21 – 28 days
- For post-exposure 4 doses 0, 3, 7 and between 14 – 28 days
- For Elderly post-exposure 5 doses at day 0, 3, 7, 14 and 28

# Respiratory Syncytial Virus

USFDA recently approved RSV vaccine on the basis of robust results showing reduced risk for severe RSV-associated lower respiratory tract disease (LRTD).<sup>22,23</sup>

<b>Vaccine type:</b> Recombinant Vaccine with Adjuvant   Recombinant Vaccine without Adjuvant											
<b>Route of administration:</b> Intramuscular injection (IM)											
<b>Dose:</b> 0.5 ml   1 dose											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Contraindication:</b> History of severe allergic reaction (eg., anaphylaxis) to any component of the vaccine											
<b>Guideline recommendations for Respiratory Syncytial Virus vaccines in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
-	-	-	-	-	-	-	Age 60 years or older: Based on shared clinical decision-making, 1 dose - Pregnant at 32 weeks 0 days through 36 weeks and 6 days gestation from September through January in most of the continental United States*: 1 dose				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 59 years</b>											
Age ≥60 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>R</b>	<b>R*</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>
*If available only non adjuvant vaccine may be considered. <b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

## Key considerations:

- For the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in individuals 60 years of age and older
- For pregnant person at 32 weeks 0 days through 36 weeks and 6 days gestation at risk of RSV infection - Only Recombinant Vaccine without Adjuvant should be used

\*\*Not yet approved for clinical use in India\*\*

# Typhoid

<p><b>Vaccine Type:</b> <b>Inactivated typhoid vaccine</b></p> <p><b>Dose:</b> 0.5 ml <b>Route:</b> IM <b>Time:</b> At least 2 weeks <b>Booster:</b> Every 2 years before travel if risk continues</p>	<p><b>Vi Polysaccharides Vaccine (ViPS)</b></p> <p><b>Dose:</b> 0.5 ml <b>Route:</b> IM <b>Booster:</b> Every 3 years</p>	<p><b>Typhoid conjugate vaccine (TCV)</b></p> <p><b>Dose:</b> 0.5 ml <b>Route:</b> IM <b>Age:</b> 2 years and older <b>Booster:</b> Maybe given after 3 yrs.</p>	<p><b>Live typhoid vaccine</b></p> <p><b>Route:</b> orally <b>Dose:</b> One capsule is taken every other day, for a total of 4 capsules <b>Age:</b> 6 years and older. <b>Booster:</b> Every 5 years, if at risk <b>Contraindications:</b> Pregnant women, history of allergic reaction to any excipients of the vaccine, immunocompromised</p>								
<b>If available Typhoid Conjugated Vaccine should be preferred</b>											
<b>Guideline recommendations for Typhoid vaccines in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
1 dose ViPS repeat 2 yearly OR 1 dose TCV up to 45 yrs.	Recommended	Outbreak or high-risk travelers (3 doses, repeat 3-yearly)	-	≤18 years: TCV 1 dose; >18 years: ViPS 3 yearly	-	-	Outbreak or high-risk- ≤18 years: TCV 1 dose travelers (3 doses, repeat 3-yearly)- >18 years				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 59 years</b>											
Age ≥50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>BR</b>	<b>R</b>	<b>R</b>
<p><b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit</p>											

## Key considerations:

- Professional food handlers
- Unvaccinated Adults age 18 through 45 yrs may be given TCV in endemic areas
- Travelers at risk of exposure
- During outbreaks
- In pregnant females always weigh the benefit vs. risk before giving the vaccine\*

\*Do not use live vaccine if pregnant.

## Shingles (Herpes Zoster)

<b>Vaccine type:</b> Recombinant zoster vaccine											
<b>Route of administration:</b> For, intramuscular injection only, preferably in the deltoid muscle											
<b>Dose:</b> 2 doses 0.5 ml   2-6 months apart											
<b>Storage:</b> Do not expose to direct sunlight or heat, should be stored between 2°C and 8°C.											
<b>Guideline recommendations for Shingles vaccine in adults</b>											
API <sup>6</sup>	RSSDI <sup>7</sup>	ISN <sup>8</sup>	GSI <sup>9</sup>	IMA <sup>10</sup>	FOGSI <sup>11,12</sup>	NHM <sup>13</sup>	CDC <sup>14</sup>				
≥50 years (1 dose – Live or 2 doses Recombinant)	>50 years & above (2 doses)	≥60 years (2 doses 2-6 mo. apart)	-	-	-	-	≥50 years (2 doses 2-6 mo. apart)				
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age ≥50 yrs	Pregnancy	Immuno- compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
<b>R</b>	<b>NR</b>	<b>R</b>	<b>R</b>	<b>AR</b>	<b>AR</b>	<b>R</b>	<b>AR</b>	<b>AR</b>	<b>AR</b>	<b>NR</b>	<b>NR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

### Key considerations:

- Recommended in patients with immune compromising conditions including HIV: 2 doses 2-6 months apart (minimum gap 4 weeks)

## Yellow fever

<b>Vaccine type:</b> Live attenuated vaccine											
<b>Route of administration:</b> Intramuscular injection (IM)											
<b>Dose:</b> 0.5 ml   1 dose											
<b>Storage:</b> Should be stored between 2°C and 8°C.											
<b>Contraindication:</b> History of allergic reaction   Egg allergy   pregnancy & lactation   Immunosuppression <sup>#</sup>											
<b>Contraindication:</b> <ul style="list-style-type: none"> <li>• Symptomatic HIV infection or AIDS • Malignant neoplasms • Primary immunodeficiencies</li> <li>• Transplant: solid organ transplant, bone marrow transplant recipients within 2 years of transplant, or persons whose transplants occurred &gt;2 years ago but who are still taking immunosuppressive drugs</li> <li>• Immunosuppressive or immunomodulatory therapy: For example, corticosteroids, alkylating agents, antimetabolites, TNF-<math>\alpha</math> inhibitors, IL-1 blocking agents, monoclonal antibodies targeting immune cells</li> <li>• Recent radiation therapy</li> </ul>											
<b>Guideline recommendations for yellow fever vaccine in adults</b>											
<b>API<sup>6</sup></b>	<b>RSSDI<sup>7</sup></b>	<b>ISN<sup>8</sup></b>	<b>GSI<sup>9</sup></b>	<b>IMA<sup>10</sup></b>			<b>FOGSI<sup>11,12</sup></b>	<b>NHM<sup>13</sup></b>		<b>CDC<sup>14</sup></b>	
1 or 2 doses based on immune status	-	-	-	At risk, booster every 10 years if risk persists			-	Traveler		1 or 2 doses based on immune status	
<b>Indian Consensus Recommendations:</b>											
<b>Age 18 - 49 years</b>											
Age $\geq$ 50 yrs	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart  lung disease	CLD  alcoholism	DM	HCP	Traveller	Mass gathering
	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>NR</b>	<b>R</b>	<b>NR</b>
<b>R:</b> Recommended   <b>NR:</b> Not recommended   <b>BR:</b> May be considered after benefit risk evaluation   <b>AR:</b> With additional risk   <b>CKD:</b> Chronic kidney disease   <b>HD:</b> Haemodialysis   <b>DM:</b> Diabetes mellitus   <b>CLD:</b> Chronic liver disease   <b>HCP:</b> Health care personnel   <b>CV:</b> Cardiovascular   <b>ICU:</b> Intensive care unit											

### Key considerations:

- Not routinely recommended • Travel to certain high-risk countries: 1 dose
- Usually not recommended during pregnancy, and should try to postpone travel; however, if travel cannot be avoided 1 dose can be administered after a thorough benefit vs. risk evaluation
- For most people, a single dose of yellow fever vaccine provides long-lasting protection and a booster dose of the vaccine is not
  - vaccinated before nine months of age
  - HIV/AIDS
  - on immunosuppressive therapy
  - Laboratory workers who handle wild-type yellow fever virus

\*\* Make sure to check the updated list of recognised centres by the government of India for Yellow Fever Vaccine<sup>24\*\*</sup>

# Closing the Gap: Bridging the Need for Childhood Vaccines into Adult Healthcare

Rotavirus and Bacille Calmette-Guérin (BCG) vaccines have historically been utilized primarily in pediatric populations for the prevention of rotavirus gastroenteritis and tuberculosis (TB), respectively. However, their use in adults has not been routinely recommended due to various factors including perceived low disease burden, incomplete efficacy data, and potential safety concerns. Nevertheless, emerging evidence suggests potential benefits of these vaccines in adult populations, particularly in specific high-risk groups.<sup>25,26</sup>

**Rotavirus Vaccine:** Immunocompromised adults, older adults, and individuals with underlying medical conditions may benefit from

rotavirus vaccination to prevent severe gastroenteritis and related complications. Further studies are needed to evaluate the efficacy, safety, and cost-effectiveness of rotavirus vaccination in these populations.<sup>26</sup>

**BCG Vaccine:** High-risk groups such as health-care workers, individuals with HIV infection, and those living in settings with a high prevalence of tuberculosis may benefit from BCG vaccination to reduce the risk of TB infection and disease progression. Future research should focus on optimizing BCG vaccination strategies in adults, including the development of novel vaccine formulations and delivery methods.<sup>25</sup>

---

## Consensus Recommendations

In the proposed classification framework, vaccine recommendations are stratified into three tiers: Vital, Essential, and Desirable.

Vital recommendations encompass vaccines critical for public health, targeting diseases with high morbidity and mortality rates, emphasizing universal coverage to achieve herd immunity.

Essential recommendations focus on controlling diseases with moderate to high burdens,

prioritizing targeted vaccination strategies to reduce disease impact effectively.

Desirable recommendations include vaccines offering additional health benefits, but may require individual risk assessment and careful consideration of factors like cost-effectiveness.

This framework enables nuanced prioritization of vaccines, optimizing resource allocation, and informing public health policies for maximal impact on population health.

# Indian Consensus Recommendations

## Health Care Personnel

Vaccines	Dose	Frequency	Recommendation Rank
Influenza	1	Annually	Essential
Typhoid	1	3-7 years in endemic setup	Desirable
Tdap	1	Every 10 years	Vital
Hepatitis B	3 doses (0, 1 and 6 mo.)	Every 5 years	Vital
MMR	2 doses to non-immunized (at least 28 days apart)	--	Vital
Covid-19	1	Annually	Essential
Chickenpox	2 doses	--	Vital
Pneumococcal	PCV13 followed by PPSV23 1 year later	PPSV23 booster dose after 5 years	Essential

## Patients with Chronic Conditions

Diabetes Mellitus			
Influenza (inactivated)	1	Annually	Desirable
HPV	Female: 2 or 3 doses $\leq$ 26 years	--	Vital
	Males: 2 or 4 doses $\leq$ 21 years	--	Vital
Tdap   Td	1	Every 10 years	Vital
Hepatitis B	2 doses	--	Vital
Pneumococcal	PCV13 followed by PPSV23 1 year later	1 PPSV23 booster dose after 5 years	Essential
Covid-19	1	Annually	Essential
MMR	1 or 2 doses depending on the condition	--	Vital
Chickenpox	2 doses 4 – 8 weeks apart	--	Vital
Shingles (Herpes Zoster)	2 doses 2-6 months apart (4-8 weeks for patients on chemotherapy)	--	Essential

## Patients with Chronic Conditions

Chronic Liver Disease   Alcoholism			
Influenza (inactivated)	1	Annually	Desirable
HPV	Female: 2 or 3 doses ≤26 years	--	Vital
	Males: 2 or 4 doses ≤21 years	--	Vital
Tdap   Td	1	Every 10 years	Vital
Hepatitis B	2 doses	--	
Pneumococcal	1 dose PCV13 followed by 1 dose of PPSV23 1 year later	1 booster dose of PPSV23 after 5 years	Essential
Covid-19	1	Annually	Essential
MMR	1 or 2 doses depending on the condition	--	Vital
Chickenpox	2 doses 4 – 8 weeks apart	--	Vital
Meningococcal	2 doses 4 weeks apart	--	Desirable
Heart or Lung Disease			
Influenza (inactivated)	1	Annually	Desirable
HPV	Female: 2 or 3 doses ≤26 years	--	Vital
	Males: 2 or 4 doses ≤21 years	--	Vital
Tdap   Td	1	Every 10 years	Vital
Pneumococcal	PCV13 followed by PPSV23 1 year later	1 PPSV23 booster dose after 5 years	Essential
Covid-19	1	Annually	Essential
MMR	1 or 2 doses depending on the condition	--	Vital
Chickenpox	1 or 2 doses depending on the indication	--	Vital
Shingles (Herpes Zoster)	2 doses 2-6 months (4-8 weeks for patients on chemotherapy)	--	Essential
Meningococcal	2 doses 4 weeks apart (age >50 years)	--	Desirable

## Patients with Chronic Conditions

<b>CKD   Haemodialysis</b>			
Influenza (inactivated)	1	Annually	Desirable
Hepatitis B	3 doses	0, 1, and 6 months and a booster after 5 years	Vital
HPV	Female: 2 or 3 doses ≤26 years	--	Vital
	Males: 2 or 4 doses ≤21 years	--	Vital
Tdap   Td	1	Every 10 years	Vital
Pneumococcal	PCV13 followed by PPSV23, 8 weeks later	1 PPSV23 booster dose after 5 years	Essential
Covid-19	1	Annually	Essential
MMR	1 dose	--	Vital
Chickenpox	1 or 2 doses depending on the indication	--	Vital
Shingles (Herpes Zoster)	2 doses 2-6 months apart (4-8 weeks for patients on chemotherapy)	--	Essential
<b>Asplenia   Complement Deficiency   Sickle Cell Disease</b>			
Influenza (inactivated)	1	Annually	Desirable
HPV	Female: 2 or 3 doses ≤26 years	--	Vital
	Males: 2 or 4 doses ≤21 years	--	Vital
Tdap   Td	1	Every 10 years	Vital
Pneumococcal (PCV13 + PPSV23)	1 dose of PCV13 followed by PPSV23 at least 8 weeks later	1 PPSV23 booster dose after 5 years	Essential
Covid-19	1	Annually	Essential
MMR	1 or 2 doses depending on the condition	--	Vital
Chickenpox	1 or 2 doses depending on the indication	--	Vital
Hemophilus influenzae type B	1	--	Essential

## Patients with Chronic Conditions

Individuals with Cancer			
Influenza (inactivated)	1	Annually	Desirable
Tdap	1 minimum 3 mo. after chemotherapy	Td every 10 years	Vital
Hib	1 at least 3 mo. after chemotherapy		Essential
Pneumococcal (PCV13 + PPSV23)	PCV13: 1 dose at least 3 mo. after chemotherapy PPSV23: 1 dose at least 8 weeks after PCV13	1 PPSV23 booster dose after 5 years may be considered	Essential
Covid-19	1	Annually	Essential
MMR	2 doses 4 -8 weeks apart	--	Vital
Chickenpox	2 doses 4 -8 weeks apart	--	Vital
Shingles (Herpes Zoster)	2 doses 2-6 weeks apart (4-8 weeks for patients on chemotherapy)	--	Essential

### Immunocompromised Individuals

In general, most inactivated vaccines are safe for immunocompromised individuals, and these individuals should receive all age-appropriate vaccines, including the annual influenza vaccine, pneumococcal vaccines (PCV13 and PPSV23), hepatitis B vaccine, and the meningococcal conjugate vaccine. However, live vaccines such as MMR, varicella, and the oral polio vaccine are usually contraindicated in this population due to the risk of vaccine-associated infections

### Recipients of Hematopoietic Stem Cell Transplant (HSCT)

Several factors, including the donor's immune status, type of transplant, time since transplant, ongoing immunosuppressive treatment, and the presence of graft-versus-host disease, can influence the immunization process for individuals. It is advisable to undergo a full reimmunization process starting with inactivated vaccines at least one year after bone marrow transplantation.

## Recipients of HSCT

Vaccines	Dose	Schedule	Recommendation Rank
TD TdaP	3	6 – 12 mo. after transplant	Vital
Hepatitis B	3	6 mo. after transplant	Essential
Hib	2	6 – 12 mo. after transplant followed by booster dose 2 – 6 mo. later	Essential
HPV	3	6 mo. after transplant	Vital
Influenza	1	4 – 6 mo. after transplant	Desirable
IPV	3	6 – 12 mo. after transplant	Desirable
Meningococcal conjugate	2	6 mo. after transplant	Essential
MMR	2	4 – 8 weeks apart	Vital
Pneumococcal (PCV13)	3	3 – 6 mo. after transplant, at least 4 weeks apart	Essential
Pneumococcal (PPSV23)	1	At least 8 weeks after the last dose of PCV13 and 12 months after the HSCT	Essential
Chickenpox	2	4 – 8 weeks apart	Vital
Shingles (Herpes Zoster)	2	3-12 months after transplantation 2 – 6 months apart	Essential

## Recipients of Solid Organ Transplant

An accelerated immunization schedule is recommended in donor and recipient. Below is the recommended schedule for patients and donors undergoing solid organ transplant:<sup>27</sup>

Vaccines	Recipient & Donor	Comments	Recommendation Rank
<b>Inactivated vaccines</b>			
Pneumococcal (PCV13, PPSV23)	PCV13 followed by PPSV23, 8 weeks later	Booster dose with PPSV23 after 5 years	Vital
Meningococcal	2 doses, 8 weeks apart in those at risk	Should be given before splenectomy, before eculizumab	Essential
Hib	Complete schedule	As in normal individuals	Essential
Influenza	1 dose annually	1 – 3 mo. after transplant, later results in better protection	Desirable
Hepatitis A	2 doses, 6 mo. apart	If travelling to South Asia	Desirable
Hepatitis B	3-4 doses before transplant	Booster dose if antibody titre <10mU/ml   Serology testing 4-weeks after complete dose	Desirable

Vaccines	Recipient & Donor	Comments	Recommendation Rank
<b>Inactivated vaccines</b>			
IPV	Complete Schedule	If not vaccinated previously	Desirable
Tdap	1 dose – 2 weeks before Transplant	Booster every 10 years	Vital
HPV	3 doses at 0, 2, 6 mo.	For age 11-26 years, if schedule not completed earlier	Vital
Shingles (Herpes Zoster)	2 doses      Not recommended	Preferred pre-transplant, if not possible give 6-12 mo. after transplant	Essential
Typhoid	Polysaccharide - 1 dose (Booster after 3 years)	Required: Before travel	Desirable
	Conjugated - 1 dose (No booster required)		
COVID-19	2 doses 4 weeks apart (or as per individual vaccine recommendation)	Booster as required	Essential
<b>Live Vaccines</b>			
MMR	Should be complete before transplant	Contraindicated after transplant	Vital
Varicella	Pretransplant 2 doses 1 month apart	Contraindicated after transplant	Vital
Yellow Fever	Contraindicated	Avoid travelling to Africa and South America if not vaccinated; if travel is necessary, must travel with yellow card with stamp and reason not vaccinated	

## HIV Infection or Other Immunocompromising Conditions

HIV positive and other immunocompromised states			
Vaccines	Dose	Booster	Recommendation Rank
Influenza (inactivated)	1	Annually	Desirable
Typhoid	1	3-7 years in endemic setup	Desirable
Tdap Td	1	Td every 10 years	Vital
Hepatitis B	3 doses (0, 1 and 6 mo.)	--	Essential
Pneumococcal	PCV13 followed by PPSV23 8 weeks later	Booster doses of PPSV23 after 5 years and at age 65 years	Vital
Covid-19	1	Annually	Essential
MMR	2 doses 4 weeks apart	CD4 count $\geq 200$ cells/mm <sup>3</sup> for at least 6 mo. Contraindicated for CD4 count $< 200$ cells/mm <sup>3</sup>	Vital
Varicella	2 doses 3 mo. apart	CD4 percentages $\geq 15\%$ and CD4 count $\geq 200$ cells/mm <sup>3</sup>	Vital
HPV-9	3 doses	For individuals $\leq 26$ years of age ay 0, 6 and 12 mo.	Vital
Shingles (Herpes Zoster)	2	2 – 6 mo. apart (min gap 4 week)	Essential

## During Pregnancy

Vaccines	Pregnant females	Dose	Recommendation Rank
Influenza (Flu) (IIV):	Recommended	1	Desirable
Tdap	At least one dose of Tdap vaccine is recommended during each pregnancy, preferably between 27 and 36 weeks of gestation	1	Vital
COVID-19 Vaccine	Recommended during pandemic or local epidemics	1	Essential
Hepatitis B	Recommended.	3	Essential

# Indian Consensus Recommendation for Risk Conditions

	Pregnancy	Immuno-compromised	HIV infection	Asplenia, complement deficiencies	CKD  HD	Heart   lung disease alcoholism	CLD	DM	HCP	Traveller	Mass gathering
Anthrax											
Chickenpox											
Chikungunya											
Cholera											
COVID-19											
Td											
Tdap											
Hib											
Hep A											
Hep B											
HPV											
IIV4 or RIV4											
LAIV4											
Japanese Encephalitis											
MMR											
MenACWY											
PCV13											
PPSV23											
Polio											
Rabies											
RSV											
Typhoid											
Shingles (Herpes Zoster)											
Yellow Fever											

**Legend to read the table**

Recommended	Not Recommended	Benefit Risk Ratio	Additional Risk Factor	No Guidance
-------------	-----------------	--------------------	------------------------	-------------

**CKD:** Chronic kidney disease | **HD:** Haemodialysis | **DM:** Diabetes mellitus | **CLD:** Chronic liver disease | **HCP:** Health care personnel | **CV:** Cardiovascular | **ICU:** Intensive care unit

# Indian Consensus Recommendation Based on Age

Age	18 – 26 years	27 – 49 years	50 – 64 years	≥65 years
Anthrax				
Chickenpox	Additional Risk Factor	Benefit Risk Ratio		
Chikungunya	Benefit Risk Ratio	Benefit Risk Ratio	Benefit Risk Ratio	Benefit Risk Ratio
Cholera	At risk			
COVID-19	During pandemic or epidemic			
Hib	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor
Hep A	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor
Hep B	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor
HPV	3 doses	2 doses		
IIV4 or RIV4	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor
LAIV4	Additional Risk Factor	Additional Risk Factor		
Japanese Encephalitis	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor
MMR	Additional Risk Factor	Additional Risk Factor		
MenACWY	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	
PCV13 PPSV23	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor
Polio	Additional Risk Factor			
Rabies (post-exposure)	4 doses			5 doses
RSV				Above 60 years
Tdap Td	1st dose of Tdap followed by booster dose of Td TdaP every 10 years			
Typhoid	At risk			
Shingles (Herpes Zoster)	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor	Additional Risk Factor
Yellow Fever	If risk of exposure or traveling to an endemic country			
	Recommended	Not Recommended	Benefit Risk Ratio	Additional Risk Factor
				No Guidance

## Recommendation for traveling to India

### List of recommended vaccines

**Routine:** MMR, DTaP, varicella (chickenpox), polio, Covid-19, pneumococcal and influenza vaccine status is up-to-date

**Hepatitis A:** Risk of contracting hepatitis A through contaminated food or water is high

**Typhoid:** Recommended for Travelers at risk of exposure

**Hepatitis B (if needed):** If one might have intimate contact with locals or require medical treatment during your stay

**Japanese Encephalitis:** If one plans to spend an extended period (>1 month) in rural or agricultural areas, especially during the monsoon season

**Rabies:** Plan or risk of animal exposure, pre-exposure vaccine may be given (3 doses at 0,7 and 28 days)

**Cholera:** Plan to visit or stay in outbreak-prone areas

**Polio:** OPV is mandatory for people coming from these countries Afghanistan, Ethiopia, Israel, Kenya, Nigeria, Pakistan and Somalia at least 6 weeks before planned travel to India and is valid for 1 year

**Meningococcal Meningitis:** 1 dose is recommended 10-14 days before planned travel date

**Yellow Fever:** It is mandatory for Travelers coming from Africa and South America. 1 dose in a life time is sufficient

## Students travelling from India to international destinations

It is recommended to visit individual country's immunization recommendations well in advance before travel to check for latest recommendations. However, some of the common vaccines recommended for international Travelers include:

### Routine Vaccines

Diphtheria, tetanus and pertussis	Meningococcal
Hepatitis B	Pneumococcal
Haemophilus influenzae type B	Polio
Human papillomavirus	Rotavirus
Influenza (seasonal)	Tuberculosis
Measles, mumps and rubella (MMR)	Varicella

**MMR:** Either evidence of protective antibodies or MMR vaccination is mandatory for adolescents seeking college admissions in Europe and US

**Hepatitis A:** Recommended for Travelers to areas with poor sanitation and limited access to clean water and food safety

**Typhoid:** Recommended for Travelers visiting regions with an increased risk of typhoid fever

**Yellow Fever:** Mandatory for Travelers visiting certain countries with yellow fever transmission and may require an International Certificate of Vaccination or Prophylaxis (ICVP) for entry

**Rabies:** Considered for Travelers with potential exposure to animals or remote areas with limited access to medical care (Pre-exposure 3 dose schedule should be followed at 0, 7 and 28 days)

**Japanese Encephalitis:** Recommended for Travelers to areas with Japanese Encephalitis transmission, especially during the transmission season

**Meningococcal Meningitis:** Recommended for Travelers visiting regions with a risk of meningococcal disease, especially during mass gatherings or outbreaks.

**Polio (Inactivated Polio Vaccine - IPV):** Recommended for Travelers to areas with ongoing polio transmission

**Cholera:** The oral cholera vaccine may be considered for Travelers visiting areas with active cholera outbreaks

**COVID-19 Vaccine:** Given the ongoing global pandemic, COVID-19 vaccination is essential for international travel and may be required by most countries

## Recommendation for Pilgrims

### Mandatory vaccines for mass gathering within India (e.g., Kumbh mela)

*For everyone*

*Prolonged Stay*

Typhoid

Hepatitis B

Hepatitis A

Japanese Encephalitis

Influenza

Pneumococcal

### Mandatory vaccines for mass gathering outside India (e.g., Hajj, Umrah etc.)

*For everyone*

*Prolonged Stay*

Quadrivalent Meningococcal Vaccine

Pneumococcal

Influenza

Polio

# Upcoming Vaccines


## Dengue

Several countries have licensed the first live-attenuated chimeric yellow-fever| tetravalent dengue vaccine (CYD-TDV), known as Dengvaxia. However, the vaccine has shown low efficacy in children and individuals who have not been previously exposed to dengue, and it has even increased the risk of severe dengue in such individuals. To address these issues, a heterologous prime-boost regimen using sequential immunization with DENVax and Dengvaxia has been proposed. This regimen targets all four serotypes of dengue and eliminates the adverse effect of antibody-dependent enhancement (ADE). Additionally, combining inactivated vaccines with alum and live attenuated vaccines in a heterologous prime-boost regimen may enhance the immune response. However, the lack of an ideal animal model for dengue poses challenges in vaccine development, and the macaque model is being considered for studying immunological responses similar to those observed in humans.<sup>28</sup>

In an interview with 'The Hindu', Dr. Nivedita Gupta, the Head of Virology at the Indian Council of Medical Research (ICMR), provided details about two potential vaccines. The vaccine developed by the Serum Institute of India has initiated phase 1|2 studies in the pediatric population. On the other hand, Panacea's vaccine is planning to conduct a phase III randomized, double-blind, placebo-controlled trial involving 10,335 healthy adults aged 18-80 years at 20 ICMR-funded sites. The phase III protocol has received approval from the Drugs Controller General of India in January 2023, and the company is working towards scaling up vaccine production. The trials are expected to commence in August-September of this year. The ICMR has outlined the desirable

characteristics for a dengue vaccine, which include a satisfactory short- and long-term safety profile without antibody-dependent enhancement. The vaccine should provide protection against all four serotypes of dengue, reduce the risk of severe diseases and deaths, induce a sustained immune response, and be effective regardless of the individual's previous serostatus or age.<sup>29</sup>

### Live attenuated dengue vaccine constructs<sup>28</sup>



## Human Immunodeficiency Virus (HIV)

HIV, a retrovirus with an enveloped structure and a single-stranded RNA genome, leads to the development of acquired immunodeficiency syndrome (AIDS) in its late stage. Primary infection with HIV can present symptoms within two to four weeks of the virus entering the body. Subsequently, a prolonged chronic infection ensues, which can persist for many years. AIDS is primarily characterized by the occurrence of opportunistic infections and tumours, which often result in fatality if left untreated. Several Vaccines have been developed and are undervaluation for efficacy and safety viz.; The eOD-GT8 60mer (mRNA-1644) vaccine, developed by IAVI and Scripps Research in collaboration with Moderna, safely induced

targeted immune responses in 97% of recipients in the Phase I clinical trial (IAVI G001).<sup>30,31</sup> The germline-targeting vaccine design priming strategy, demonstrated in the Phase 1 clinical study IAVI G002, supports the development of boosting regimens to generate VRC01-class bnAb responses against HIV. Another Phase 1 clinical study (IAVI G003) is currently ongoing to investigate the eOD-GT8 60mer mRNA Vaccine in African populations. Moderna Inc. is advancing three Phase I clinical trials for HIV vaccines, including mRNA-1644|IAVI G002, mRNA-1644|IAVI G003, and mRNA-1574|NIAID.<sup>32</sup> Vir Biotechnology, Inc. is developing VIR-1388,<sup>33</sup> a T cell vaccine based on the human cytomegalovirus vector platform, for HIV prevention. HOOKIPA Pharma's preclinical studies demonstrated that their 2-vector therapy for Arenaviral therapeutic vaccines induces a stronger immune response and reduces viral load.<sup>34</sup> AELIX Therapeutics S.L. reported positive results from the phase 1 clinical study of their therapeutic HIV vaccine, HIVACAT T-cell immunogen (HT,I), published in Nature Medicine.<sup>35</sup> CD40. HIVRI. Env, developed by the Vaccine Research Institute, is undergoing a phase 1 clinical study.<sup>36</sup> Uvax Bio, LLC's HIV-1 vaccine candidate will enter a Phase 1 clinical trial sponsored by the U.S. NIH in early 2024. Additionally, research has shown the potential of a single-component, self-assembling protein nanoparticle (1c-SApNP) displaying native-like Env trimers as vaccine candidates.<sup>37</sup>

## Malaria

*In a recent update, The WHO released the recommendations for RTS, S|AS01 vaccine,<sup>38</sup> is the pioneering malaria vaccine resulting from a long-standing collaboration between public and private entities that dates back to 1983. While other candidates for P. falciparum malaria*

vaccines are currently in clinical evaluation, RTS, S|AS01 stands as the first vaccine to complete Phase 3 trials and be administered to children through routine immunization programs in phased pilot introductions.<sup>39</sup> It received positive scientific opinion from the European Medicines Agency in 2015 and national regulatory authorization for use in Ghana, Kenya, and Malawi as part of the Malaria Vaccine Implementation Programme in 2019. Another trial utilized the high initial efficacy of RTS, S|AS01 by administering three primary doses at monthly intervals followed by annual single doses during the intense high transmission season. This combined approach of the vaccine and seasonal malaria chemoprevention was superior to either intervention alone. Promising candidates approaching late-stage clinical evaluation include R21|MatrixM targeting PfCSP protein and PfSPZ, an attenuated whole sporozoite vaccine.<sup>40</sup> Various technologies such as DNA and mRNA-based vaccines, adjuvants, virus-like particles, and vesicle-based platforms are being explored for the development of malaria vaccines.<sup>40-42</sup> WHO has issued guidelines and preferred product characteristics to support the ongoing research and advancement of recombinant malaria vaccines, with updates underway to incorporate recent progress in the field.

## Tuberculosis

In a phase 2b placebo-controlled study published in NEJM 2019, M72|AS01E vaccine was evaluated in patients with latent M. tuberculosis infection. Most participants had previously received the BCG vaccine. M72|AS01E provided 54.0% protection for M. tuberculosis-infected adults against active pulmonary tuberculosis disease, without evident safety concerns.<sup>43</sup> In an announcement

made on Wednesday 28<sup>th</sup> June 2023, the 26,000-person, Phase 3 study, set to begin next year, will test the vaccine's efficacy and safety. If proven effective, would be the first new tuberculosis vaccine in over a century.<sup>44</sup>

## Leprosy

National Leprosy Eradication Program (NLEP) initiated the implementation of the Mycobacterium Indicus Prani (MiP) vaccine project in India in 2016. Extensive trials, both in hospitals and among the general population, have demonstrated the dual benefits of the MiP vaccine, showcasing its immunotherapeutic and immune-prophylactic effects in individuals with multibacillary leprosy and their contacts. This vaccine has proven effective in diminishing the bacillary load, improving histopathological lesions, achieving complete granuloma clearance, reducing reactions and neuritis, and shortening the duration of multidrug therapy (MDT) for leprosy patients. In a new project conducted under the collaboration of Indian Council of Medical Research (ICMR) and NLEP, the MiP vaccine is administered to the index leprosy patient in addition to the standard MDT. Concurrently, family members and contacts of the index case receive the MiP vaccine twice, spaced six mo. apart, with the objective of fortifying their immunity to prevent leprosy upon exposure to Mycobacterium leprae from an infected patient. The immunization of the index case aims to expedite the clearance of bacteria and clinical lesions, while MiP vaccination in contacts is designed to enhance their immunity, providing protection against the development of clinical disease upon exposure to M. leprae from infected individuals.<sup>45</sup>

## Other vaccines being developed

**Zika Virus Vaccine:** Various candidates were under development by different

pharmaceutical companies, including Takeda, Moderna, and Walter Reed Army Institute of Research (WRAIR). These candidates were in various stages of preclinical and clinical development.<sup>46</sup>

**Norovirus Vaccine:** Vaxart and Takeda were among the companies working on oral norovirus vaccine candidates. These candidates were in different phases of clinical trials.<sup>47</sup>

**Group B Streptococcus (GBS) Vaccine:** Several companies, including Pfizer, GlaxoSmithKline (GSK), and Sanofi Pasteur, were involved in the development of GBS vaccine candidates. These candidates were in the preclinical and early clinical stages.<sup>48</sup>

**Staphylococcus aureus Vaccine:** Several private sector players are working on Staphylococcus aureus vaccine candidates targeting hospital-acquired infections. These candidates are in different stages of clinical trials.<sup>49</sup>

**Bacterial lysates:** Bacterial lysates are immunostimulants derived from bacterial cells that have been ruptured or lysed. These lysates contain a variety of bacterial components such as proteins, nucleic acids, and cell wall fragments, which can activate the immune system and stimulate a protective response against bacterial infections. Bacterial lysates have been used as immunotherapeutic agents in some medical settings, especially in respiratory conditions like recurrent respiratory infections and chronic obstructive pulmonary disease (COPD). While bacterial lysates have shown potential in boosting immune responses, their clinical efficacy is still a subject of ongoing research and debate. The available evidence is not yet sufficient to recommend bacterial lysates as a standard treatment for all individuals or for the prevention of bacterial infections.<sup>50</sup>

## Personalized Vaccines for Cancer

Researchers led by Dr. Vinod Balachandran at Memorial Sloan Kettering Cancer Center have developed a personalized mRNA cancer treatment vaccine for pancreatic ductal adenocarcinoma (PDAC), the most common and deadly form of pancreatic cancer. In a small clinical trial, tumour samples from 19 patients were sequenced to identify neoantigens, and personalized mRNA vaccines were created based on these findings. Participants received immune checkpoint inhibitor atezolizumab

before vaccination and then received nine doses of the personalized vaccine over several mo. Results showed that half of the patients had a strong immune response, with T cells recognizing the neoantigens. Those with a strong response remained cancer-free after a year and a half, while those with a weaker response experienced recurrence within an average of just over a year. The study demonstrates the potential of personalized vaccines to activate the immune system against pancreatic cancer and paves the way for further research and larger clinical trials.

# Conclusion

In conclusion, it is fair to say that adult vaccination plays a vital role in safeguarding individual and public health. The consensus statement emphasizes the importance of immunization in adults, highlighting the numerous benefits it offers. By ensuring high vaccination rates among adults, we can effectively prevent and control infectious diseases, protect vulnerable populations, and reduce the burden of illness within communities.

Healthcare professionals have a crucial role in promoting adult vaccination and leading by example. By prioritizing their own immunizations, they not only protect themselves but also serve as advocates for patients and the broader population. Compliance with occupational health requirements and adherence to recommended vaccination schedules contribute to a safer healthcare environment and reduce the risk of workplace outbreaks.

Further, adult vaccination goes beyond individual protection, fostering herd immunity and preventing the transmission of diseases to those who are more susceptible, such as the elderly, infants, and individuals with compromised immune systems. This collective effort is essential for minimizing the impact of vaccine-preventable diseases on public health.

In light of these considerations, it is crucial for healthcare providers, policymakers, and the public to recognize the significance of adult

vaccination and work together to overcome barriers to immunization. Efforts should be made to increase awareness, improve access to vaccines, and address vaccine hesitancy through education and evidence-based communication.

By embracing the consensus statement on adult vaccines and implementing its recommendations, we can achieve a healthier and more resilient society, where preventable diseases are kept at bay, and individuals can enjoy a higher quality of life. Investing in adult vaccination is an investment in the well-being and future of our communities.

## Disclosures and Acknowledgements

**Conflict of interests:** The authors declare no conflict of interest and the content is developed and designed by the the Association of Physicians of India in collaboration with the representatives and office bearers of CSI, CIDS, FOGSI, GSI, HFAI, IAPSM, ICS, IMA, IRA, ISCCM, ISN, ISO and RSSDI.

**Acknowledgements:** The consensus task force would like to acknowledge the research, medical writing, and publishing support of the ProAdWise Communications team and Dr Gaurav Chaudhry for bringing out this document.

# Appendix

## Screening Checklist for Contraindications to Vaccines for Adults

**Patient Information:** The following questions will help us determine which vaccines you may be given today. If you answer “yes” to any question, it does not necessarily mean you should not be vaccinated. It just means we need to ask you more questions. If a question is not clear, please ask your healthcare provider to explain it.

Question	Yes	No	Don't know
1. Are you sick today?			
2. Do you have allergies to medications, food, a vaccine ingredient, or latex?			
3. Have you ever had a serious reaction after receiving a vaccine?			
4. Do you have a long-term health problem with heart, lung, kidney, or metabolic disease (e.g., diabetes), asthma, a blood clotting disorder, no spleen, complement component deficiency, a cochlear implant, or a spinal fluid leak? Are you on long-term aspirin therapy?			
5. Do you have cancer, leukaemia, HIV/AIDS, or any other immune system problem?			
6. Do you have a parent, brother, or sister with an immune system problem?			
7. In the past 3 mo., have you taken medicines that affect your immune system, such as prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn's disease, or psoriasis; or have you had radiation treatments or anticoagulants (blood thinning medications)?			
8. Have you had a seizure or a brain or other nervous system problem?			
9. During the past year, have you received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug?			
10. Are you pregnant or is there a chance you could become pregnant during the next month?			
11. Have you received any vaccinations in the past 1 month (4 weeks)?			
12. Are you travelling internationally in foreseeable future?			

## Information for Healthcare Professionals about the Screening Checklist for Contraindications to Vaccines for Adults

Are you interested in knowing why we included a certain question on the screening checklist? If so, read the information below. If you want to find out even more, refer to individual vaccine section.

### Are you sick today? [all vaccines]

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. Mild illnesses (e.g., upper respiratory infections, diarrhoea) are NOT contraindications to vaccination. Do not withhold vaccination if a person is taking antibiotics.

### Do you have allergies to medications, food, a vaccine ingredient, or latex? [all vaccines]

An anaphylactic reaction to latex is a contraindication to vaccines that contain latex as a component or as part of the packaging (e.g., vial stoppers, prefilled syringe plungers, prefilled syringe caps). If a person has anaphylaxis after eating gelatin, do not administer vaccines containing gelatin. A local reaction to a prior vaccine dose or vaccine component, including latex, is not a contraindication to a subsequent dose or vaccine containing that component. For information on vaccines supplied in vials or syringes containing latex, see [www.cdc.gov/vaccinespubs/pinkbook/downloads/appendices/B/latex-table.pdf](http://www.cdc.gov/vaccinespubs/pinkbook/downloads/appendices/B/latex-table.pdf); for an extensive list of vaccine components, see [www.cdc.gov/vaccinespubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf](http://www.cdc.gov/vaccinespubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf). People with egg allergy of any severity can

receive any IIV, RIV, or LAIV that is otherwise appropriate for the patient's age and health status; cclIV and RIV do not contain egg antigen. When administering an influenza vaccine other than cclIV or RIV to a person with a history of severe allergic reaction to egg, or who required emergency medical intervention (e.g., epinephrine), vaccination should occur in a clinic, health department, or physician office; vaccine administration should be supervised by a healthcare provider who is able to recognize and manage severe allergic conditions.

### Have you ever had a serious reaction after receiving a vaccine? [all vaccines]

History of anaphylactic reaction (see question 2) to a previous dose of vaccine or vaccine component is a contraindication for subsequent doses. Under normal circumstances, vaccines are deferred when a precaution is present. However, situations may arise when the benefit outweighs the risk (e.g., during a community pertussis outbreak).

### Do you have a long-term health problem with heart, lung, kidney, or metabolic disease (e.g., diabetes), asthma, a blood clotting disorder, no spleen, complement component deficiency, a cochlear implant, or a spinal fluid leak?

Are you on long term aspirin therapy? [MMR, VAR, LAIV] A history of thrombocytopenia or thrombocytopenic purpura is a precaution to MMR vaccine. LAIV is not recommended for people with anatomic or functional asplenia, complement component deficiency, a cochlear implant, or CSF leak. Underlying health conditions of the heart, lung, kidney, or metabolic disease (e.g., diabetes) and asthma are considered precautions for the use of LAIV. Aspirin use is a precaution to VAR.

### Do you have cancer, leukemia, HIV/AIDS, or any other immune system problem? [LAIV, MMR, VAR]

Live virus vaccines (e.g., LAIV, MMR, VAR) are

usually contraindicated in immunocompromised people. However, there are exceptions. For example, MMR vaccine is recommended and VAR vaccine may be considered for adults with CD4+ T-lymphocyte counts of greater than or equal to 200 cells/μL. Immuno-suppressed people should not receive LAIV.

**Do you have a parent, brother, or sister with an immune system problem? [MMR, VAR]**

MMR or VAR vaccines should not be administered to persons who have a family history of congenital or hereditary immunodeficiency in first-degree relatives (i.e., parents and siblings), unless the immune competence of the potential vaccine recipient has been substantiated clinically or verified by a laboratory.

**In the past 3 mo., have you taken medicines that affect your immune system, such as cortisone, prednisone, other steroids, or anticancer drugs; drugs for the treatment of rheumatoid arthritis, Crohn's disease, or psoriasis; or have you had radiation treatments? [LAIV, MMR, VAR]**

Live virus vaccines (e.g., LAIV, MMR, VAR) should be postponed until after chemotherapy or long-term high-dose steroid therapy has ended. For details and length of time to postpone, see references in Notes above. Some immune mediator and immune modulator drugs (especially the anti-tumor necrosis factor agents adalimumab, infliximab, etanercept, golimumab, and certolizumab pegol) may be immunosuppressive. A comprehensive list of immunosuppressive immune modulators is available in CDC Health Information for International Travel (the "Yellow Book") available at [wwwnc.cdc.gov/travel/yellowbook/2020/trav](http://wwwnc.cdc.gov/travel/yellowbook/2020/trav)

elerswith-additional-considerations/immunocompromised-travelers. The use of live virus vaccines should be avoided in persons taking these drugs. To find specific vaccination schedules for stem cell transplant (bone marrow transplant) patients.

**Have you had a seizure or a brain or other nervous system problem? [influenza, Td/Tdap]**

Tdap is contraindicated in people who have a history of encephalopathy within 7 days following DTP/DTaP. An unstable progressive neurologic problem is a precaution to the use of Tdap. For people with stable neurologic disorders (including seizures) unrelated to vaccination, or for people with a family history of seizure, vaccinate as usual. A history of Guillain-Barré syndrome (GBS) is a consideration with the following: 1) Td/Tdap: if GBS has occurred within 6 weeks of a tetanus toxoid vaccine and decision is made to continue vaccination, give Tdap instead of Td if no history of prior Tdap; 2) Influenza vaccine (IIV/LAIV): if GBS has occurred within 6 weeks of a prior influenza vaccine, vaccination should generally be avoided unless the benefits outweigh the risks (for those at higher risk for complications from influenza).

**During the past year, have you received a transfusion of blood or blood products, or been given immune (gamma) globulin or an antiviral drug? [MMR, VAR]**

Certain live virus vaccines (e.g., MMR, LAIV, VAR) may need to be deferred, depending on several variables. Consult General Best Practice Guidelines for Immunization (referenced in Notes above) for current information on intervals between antiviral drugs, immune globulin or blood product administration and live virus vaccines.

## Are you pregnant or is there a chance you could become pregnant during the next month? [HPV, HepB, IPV, LAIV, MenB, MMR, VAR]

Live virus vaccines (e.g., MMR, VAR, LAIV) are contraindicated one month before and during pregnancy because of the theoretical risk of virus transmission to the fetus. Sexually active women in their childbearing years who receive live virus vaccines should be instructed to avoid pregnancy for one month following receipt of the vaccine. IPV and MenB vaccination should be limited to those with an elevated risk of exposure during pregnancy. IIV and Tdap are both recommended during pregnancy. Two brands of hepatitis B vaccine (HepLisav-B and PreHevbrio) are not recommended during

pregnancy due to a lack of safety data in this population; pregnant people needing hepatitis B vaccination should receive Engerix-B or Recombivax-HB, which are known to be safe and effective during pregnancy. HPV vaccine is not recommended during pregnancy.

## Have you received any vaccinations in the past 4 weeks? [LAIV, MMR, VAR, yellow fever]

People who were given either LAIV or an injectable live virus vaccine (e.g., MMR, VAR, yellow fever) should wait 28 days before receiving another live virus vaccination (30 days for yellow fever). Inactivated vaccines may be given at any spacing interval if they are not administered simultaneously.

---

### Abbreviations:

**LAIV:** Live attenuated influenza vaccine | **HPV:** Human papillomavirus vaccine | **IIV:** Inactivated influenza vaccine | **ccIIV:** Cell culture inactivated influenza vaccine | **IPV:** Inactivated poliovirus vaccine | **MMR:** Measles, mumps, and rubella vaccine | **RIV:** Recombinant influenza vaccine | **Td|Tdap:** Tetanus, diphtheria, (acellular pertussis) vaccine | **VAR:** Varicella vaccine | **MenB:** meningitis B | **HIV:** Human immunodeficiency virus vaccine

# Storage best practices for refrigerated vaccines-celsius (C)

## 1 Unpack vaccines immediately

- Place the vaccines in trays or containers for proper airflow.
- Put vaccines that are first to expire in front.
- Keep vaccines in original boxes with lids closed to prevent exposure to light.
- Separate and label vaccines by type and public (VFC) or private.




## 2 Store vaccines at ideal temperature: 5°C



Never freeze refrigerated vaccines!

Exception: MMR can be stored in a refrigerator or freezer

### Refrigerated vaccines



Report out-of-range temperatures immediately!


## 3 Use vaccine storage best practices

### DO

- ⊘ Do make sure the refrigerator door is properly closed!
- ⊘ Do replace crisper bins with water bottles to help maintain consistent temperature.
- ⊘ Do lable water bottles "Do Not Drink."
- ⊘ Do leave 2 to 3 inches between vaccine containers and refrigerator walls.
- ⊘ Do post "Do Not Unplug" signs on refrigerator and near electrical outlet.

### DON'T

- ✓ Don't use dormitory-style refrigerator.
- ✓ Don't use top shelf for vaccine storage.
- ✓ Don't put food or beverages in this refrigerator.
- ✓ Don't put vaccines on door shelves or on the floor of refrigerator.



Vaccines	Exposure to heat   light	Exposure to cold
<b>Heat and light sensitive vaccines</b>		
OPV	Sensitive to heat	Not damaged by freezing
Measles   MR	Sensitive to heat and light	Not damaged by freezing
BCG, RVV and JE	Relatively heat stable but sensitive to light	Not damaged by freezing
<b>Freeze sensitive vaccines</b>		
Hep B   Penta   PCV	Relatively heat stable	Freezes at -0.5°C (should not be frozen)
IPV, DPT, and TT	Relatively heat stable	Freezes at -3°C (should not be frozen)

**At the PHC level, all vaccines are kept in the ILR for a period of one month at temperature of +2°C to +8°C**

Vaccines sensitive to heat

- BCG (after reconstitution)
- OPV
- IPV
- MR
- Rotavirus
- JE
- DPT
- BCG (before reconstitution)
- TT

Most sensitive



Least sensitive

Vaccine sensitive to freezing

- Hep B
- PCV
- Penta
- IPV
- DPT
- TT

Most sensitive



Least sensitive

**PCV:** Pneumococcal conjugate vaccine. **RVV:** Rotavirus vaccine. **JE:** Japanese encephalitis. **Penta:** DTwP+HiB+HepB. **DTwp:** Diphtheria, tetanus, whole cell pertussis; **HiB:** Haemophilus conjugate type B. **HepB:** Hepatitis B.

# Frequently Asked Questions on Adult Immunization<sup>51,52</sup>

## 1. Why are vaccinations important for adults?

Vaccinations are essential for adults to protect themselves from preventable diseases and to help reduce the spread of infections to vulnerable populations. Vaccines can also provide immunity to certain illnesses, which is especially important as we age and our immune systems may weaken.

## 2. Which vaccines are recommended for adults?

The specific vaccines recommended for adults can vary based on factors such as age, health status, and lifestyle. However, some common vaccines recommended for adults include influenza (flu) vaccine, Tdap (tetanus, diphtheria, and pertussis) vaccine, pneumococcal vaccine, shingles vaccine, and HPV (human papillomavirus) vaccine for certain age groups.

## 3. How often do adults need to be vaccinated?

The vaccination schedule for adults can vary depending on the type of vaccine and individual risk factors. In general, some vaccines require periodic boosters, while others may be given once or twice in a lifetime. It's essential to consult with a healthcare provider to determine the appropriate vaccination schedule for each person.

## 4. Are vaccines safe?

Most people experience minimal side effects from vaccinations, such as soreness at the injection site or mild flu-like symptoms. Serious side effects are rare. It's crucial to discuss any concerns about potential side effects with a healthcare provider before receiving a vaccine.

## 5. Can adults get vaccinated if they have certain medical conditions?

In many cases, adults with certain medical conditions can and should get vaccinated. However, the suitability of specific vaccines may depend on the individual's health status and medical history. Those with severe allergies to vaccine components or a history of adverse reactions to vaccines may need to avoid certain vaccinations.

## 6. Can pregnant women receive vaccines?

Some vaccines are safe and recommended during pregnancy, such as the influenza vaccine and the Tdap vaccine. However, other live vaccines, like the MMR (measles, mumps, and rubella) vaccine, are typically not given during pregnancy. Pregnant women should consult their healthcare provider to determine which vaccines are appropriate for them.

## 7. Are there any vaccines recommended for Travelers?

Yes, some vaccines are recommended for Travelers, especially if they are visiting areas with specific infectious disease risks. These may include vaccines for diseases such as yellow fever, typhoid, hepatitis A, and others. Travelers should consult a healthcare provider well in advance of their trip to discuss recommended vaccinations.

## 8. Are vaccines covered by insurance?

Many health insurance plans cover recommended vaccinations for adults. However, coverage may vary depending on the specific insurance policy. It's best to check with the insurance provider to determine coverage details.

**9. Do vaccines have damaging and long-term side-effects that are yet unknown. can vaccination be fatal?**

The 1998 study which raised concerns about a possible link between measles-mumps-rubella (MMR) vaccine and autism was later found to be seriously flawed, and the paper has been retracted by the journal that published it. Vaccines are very safe. Most vaccine reactions are usually minor and temporary, such as a sore arm or mild fever. Very serious health events are extremely rare and are carefully monitored and investigated. One is far more likely to be seriously injured by a vaccine-preventable disease than by a vaccine. For example, in the case of polio, the disease can cause paralysis, measles can cause encephalitis and blindness, and some vaccine-preventable diseases can even result in death. While any serious injury or death caused by vaccines is one too many, the benefits of vaccination greatly outweigh the risk, and many, many more injuries and deaths would occur without vaccines.

**10. Vaccine-preventable diseases are almost eradicated in our country, so there is no reason to be vaccinate?**

Although vaccine preventable diseases have become uncommon in many countries, the infectious agents that cause them continue to circulate in some parts of the world. In a highly inter-connected world, these agents can cross geographical borders and infect anyone who is not protected. In western Europe, for example, measles outbreaks have occurred in unvaccinated populations in Austria, Belgium, Denmark, France, Germany, Italy, Spain, Switzerland and the United Kingdom since 2005. So, two key reasons to continue vaccinating are to protect ourselves and to protect those around us. Successful vaccination programmes, like successful societies, depend on the cooperation of every individual to ensure the good of all. We should not rely on people around us to stop the spread of disease; we, too, must do what we can.

**11. Giving more than one vaccine at a time can increase the risk of harmful side-effects, which can overload an individual's immune system.**

Scientific evidence shows that giving several vaccines at the same time has no adverse effect on immune system. People are exposed to several hundred foreign substances that trigger an immune response every day. The simple act of eating food introduces new antigens into the body, and numerous bacteria live in the mouth and nose. One is exposed to far more antigens from a common cold or sore throat than they are from vaccines. Key advantages of having several vaccines at once is fewer clinic visits, which saves time and money, and individuals are more likely to complete the recommended vaccinations on schedule. Also, when it is possible to have a combined vaccination, e.g. for measles, mumps and rubella, that means fewer injections.

**12. Is it better to be immunized through disease than through vaccines?**

Vaccines interact with the immune system to produce an immune response similar to that produced by the natural infection, but they do not cause the disease or put the immunized person at risk of its potential complications. In contrast, the price paid for getting immunity through natural infection might be mental retardation from Haemophilus influenzae type b (Hib), birth defects from rubella, liver cancer from hepatitis B virus, or death from measles.

# Precautions & Contraindications for vaccines<sup>53-55</sup>

Vaccines	Contraindicated or Not Recommended	Precautions
Influenza, egg-based, inactivated injectable (IIV4)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)</li> <li>Severe allergic reaction (e.g., anaphylaxis) to any vaccine component<sup>3</sup> (excluding egg)</li> </ul>	<ul style="list-style-type: none"> <li>Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine</li> <li>Moderate or severe acute illness with or without fever</li> </ul>
Influenza, cell culture-based inactivated injectable [(ccIIV4), Quadrivalent]	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component 3 of ccIIV4</li> </ul>	<ul style="list-style-type: none"> <li>GBS within 6 weeks after a previous dose of any type of influenza vaccine</li> <li>Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, RIV, or LAIV of any valency. If using ccIIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist.</li> <li>Moderate or severe acute illness with or without fever</li> </ul>
Influenza, recombinant injectable [(RIV4), Quadrivalent]	Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component 3 of RIV4	<ul style="list-style-type: none"> <li>GBS within 6 weeks after a previous dose of any type of influenza vaccine. Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IIV, ccIIV, or LAIV of any valency. If using RIV4, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist</li> <li>Moderate or severe acute illness with or without fever</li> </ul>

Vaccines	Contraindicated or Not Recommended	Precautions
Influenza, live attenuated [LAIV4, Quadrivalent]	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, cclIV, RIV, or LAIV of any valency)</li> </ul>	<ul style="list-style-type: none"> <li>GBS within 6 weeks after a previous dose of any type of influenza vaccine</li> <li>Asthma in persons aged 5 years old or older</li> </ul>
Influenza, live attenuated [LAIV4, Quadrivalent]	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) to any vaccine component<sup>3</sup> (excluding egg)</li> <li>Anatomic or functional asplenia</li> <li>Immunocompromised due to any cause including, but not limited to, medications and HIV infection</li> <li>Close contacts or caregivers of severely immunosuppressed persons who require a protected environment</li> <li>Pregnancy</li> <li>Cochlear implant</li> <li>Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear, or any other cranial CSF leak</li> <li>Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days.</li> </ul>	<ul style="list-style-type: none"> <li>Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection [e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus)] M</li> <li>Moderate or severe acute illness with or without fever</li> </ul>
Haemophilus influenzae type b (Hib)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</li> <li>History of severe allergic reaction to dry natural latex</li> </ul>	<ul style="list-style-type: none"> <li>Moderate or severe acute illness with or without fever</li> </ul>
Hepatitis A (Hep A)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component<sup>3</sup> including neomycin</li> </ul>	<ul style="list-style-type: none"> <li>Moderate or severe acute illness with or without fever</li> </ul>
Hepatitis B (Hep B)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component<sup>3</sup> including yeast</li> <li>Pregnancy: are not recommended due to lack of safety data in pregnant persons. Use other hepatitis B vaccines if HepB is indicated</li> </ul>	<ul style="list-style-type: none"> <li>Moderate or severe acute illness with or without fever</li> </ul>

Vaccines	Contraindicated or Not Recommended	Precautions
Hepatitis A-Hepatitis B vaccine [Hep A-Hep B, (Twinrix®)]	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component<sup>3</sup> including neomycin and yeast</li> </ul>	<ul style="list-style-type: none"> <li>Moderate or severe acute illness with or without fever</li> </ul>
Human papillomavirus (HPV)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component<sup>3</sup></li> <li>Pregnancy: HPV vaccination not recommended</li> </ul>	<ul style="list-style-type: none"> <li>Moderate or severe acute illness with or without fever</li> </ul>
Measles, mumps, rubella (MMR)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</li> <li>Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)</li> <li>Pregnancy</li> <li>Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent</li> </ul>	<ul style="list-style-type: none"> <li>Recent (<math>\leq 11</math> mo.) receipt of antibody-containing blood product (specific interval depends on product)</li> <li>History of thrombocytopenia or thrombocytopenic purpura</li> <li>Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing</li> <li>Moderate or severe acute illness with or without fever</li> </ul>
Meningococcal ACWY (MenACWY)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component <sup>3</sup></li> <li>For MenACWY-D and MenACWY-CRM only: severe allergic reaction to any diphtheria toxoid-or CRM197-containing vaccine</li> <li>For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine</li> </ul>	<ul style="list-style-type: none"> <li>Moderate or severe acute illness with or without fever</li> </ul>
Meningococcal B (MenB)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</li> </ul>	<ul style="list-style-type: none"> <li>Pregnancy</li> <li>For MenB-4C only: Latex sensitivity</li> <li>Moderate or severe acute illness with or without fever</li> </ul>

Vaccines	Contraindicated or Not Recommended	Precautions
Pneumococcal conjugate (PCV13, PCV15 & PCV20)	<ul style="list-style-type: none"> <li>• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component<sup>3</sup></li> <li>• Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid-containing vaccine or to its vaccine component</li> </ul>	<ul style="list-style-type: none"> <li>• Moderate or severe acute illness with or without fever</li> </ul>
Pneumococcal polysaccharide (PPSV23)	<ul style="list-style-type: none"> <li>• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</li> </ul>	<ul style="list-style-type: none"> <li>• Moderate or severe acute illness with or without fever</li> </ul>
Haemophilus influenzae type b (Hib)	<ul style="list-style-type: none"> <li>• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</li> <li>• History of severe allergic reaction to dry natural latex</li> </ul>	<ul style="list-style-type: none"> <li>• Moderate or severe acute illness with or without fever</li> </ul>
Tetanus, diphtheria, and acellular pertussis (Tdap) Tetanus, diphtheria (Td)	<ul style="list-style-type: none"> <li>• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component<sup>3</sup></li> <li>• For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days of administration of previous dose of DTP, DTaP, or Tdap</li> </ul>	<ul style="list-style-type: none"> <li>• Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid-containing vaccine</li> <li>• History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid-containing or tetanus-toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus-toxoid-containing vaccine</li> <li>• Moderate or severe acute illness with or without fever</li> <li>• For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized</li> </ul>
Chickenpox	<ul style="list-style-type: none"> <li>• Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component<sup>3</sup></li> <li>• Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)</li> <li>• Pregnancy</li> <li>• Family history of altered immunocompetence, unless verified clinically or by laboratory testing as immunocompetent</li> </ul>	<ul style="list-style-type: none"> <li>• Moderate or severe acute illness with or without fever</li> </ul>

Vaccines	Contraindicated or Not Recommended	Precautions
Shingles (Herpes Zoster)	<ul style="list-style-type: none"> <li>Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component</li> </ul>	<ul style="list-style-type: none"> <li>Moderate or severe acute illness with or without fever</li> <li>Current herpes zoster infection</li> </ul>
Respiratory Syncytial Virus	<ul style="list-style-type: none"> <li>History of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine</li> </ul>	<ul style="list-style-type: none"> <li>Potential Risk of Preterm Birth</li> <li>Immunocompromised individuals</li> </ul>
Polio	<ul style="list-style-type: none"> <li>History of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine</li> </ul>	<ul style="list-style-type: none"> <li>Pregnancy</li> <li>Moderate or severe acute illness with or without fever</li> </ul>
Cholera	<ul style="list-style-type: none"> <li>History of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine</li> <li>aged &lt;2 years or in adults aged ≥65 yrs</li> </ul>	<ul style="list-style-type: none"> <li>Pregnancy &amp; Breast Feeding</li> <li>Altered Immunocompetence</li> </ul>
Chikungunya	<ul style="list-style-type: none"> <li>History of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine</li> </ul>	<ul style="list-style-type: none"> <li>History of anthrax disease</li> <li>Pregnancy &amp; Breast Feeding</li> <li>Altered Immunocompetence</li> <li>Moderate or severe acute illness with or without fever</li> </ul>
Yellow Fever	<ul style="list-style-type: none"> <li>History of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine</li> <li>Thymus disorder associated with abnormal immune cell function</li> <li>Immunosuppression from the following: <ul style="list-style-type: none"> <li>Symptomatic HIV infection or AIDSa</li> <li>Malignant neoplasms</li> <li>Primary immunodeficiencies</li> <li>Transplantation</li> <li>Immunosuppressive or immunomodulatory therapy</li> <li>Radiation therapy</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Pregnancy</li> <li>Breastfeeding</li> <li>Adults ≥60 years of age</li> <li>Asymptomatic HIV</li> <li>infection with CD4+</li> <li>value of 200 mm<sup>3</sup> – 500 mm<sup>3</sup></li> </ul>

# Diary for Adult Immunization

# Adult Vaccination Diary

Name			
Date of Birth		Age	___ years, ___ mo.
Contact Number			

## Annual Vaccines

	Dose 1	Dose 2	Dose 3	Repeat Dose	Dose Frequency
COVID-19	Today	<i>Not Applicable</i>	<i>Not Applicable</i>	1 year	Annually, only during pandemic  epidemic
Influenza	Today	<i>Not Applicable</i>	<i>Not Applicable</i>	1 year	Annually

## Repeat Doses

	Dose 1	Dose 2	Dose 3	Repeat Dose	Dose Frequency
Meningococcal Conjugated	Today	14 days (for high risk conditions)	<i>Not Applicable</i>	5 year	5-yearly, if at risk
Meningococcal PBCP	Today	6 mo.	<i>Not Applicable</i>	2 year	2-3 years later, if at risk
Pneumococcal (PCV13+PPSV23)	Today (PCV13)	1 year (PPSV23)	<i>Not Applicable</i>	5 yrs (PPSV23, if needed)	Not Applicable
Tdap Td	Today	<i>Not Applicable</i>	<i>Not Applicable</i>	10 year	10-yearly

Once in Life-time	Dose 1	Dose 2	Dose 3	Repeat Dose	Dose Frequency
Hib	Today	<i>Not Applicable</i>	<i>Not Applicable</i>	<i>Not Applicable</i>	Once in lifetime
Hepatitis A	Today	6-12 mo.	<i>Not Applicable</i>	<i>Not Applicable</i>	Once in lifetime
Hepatitis B	Today	1 mo.	6 mo.	<i>Not Applicable</i>	Once in lifetime
Chickenpox	Today	1 mo.	<i>Not Applicable</i>	<i>Not Applicable</i>	Once in lifetime
HPV	Today	1 mo.	6 mo.	<i>Not Applicable</i>	Once in lifetime
MMR	Today	1 mo.	<i>Not Applicable</i>	<i>Not Applicable</i>	Once in lifetime
RSV	Today	<i>Not Applicable</i>	<i>Not Applicable</i>	<i>Not Applicable</i>	Once in lifetime
Shingles (Herpes Zoster)	Today	2 mo.	<i>Not Applicable</i>	<i>Not Applicable</i>	Once in lifetime

## Other Vaccines

_____	Today				Please refer to section on individual vaccines
_____	Today				Please refer to section on individual vaccines
_____	Today				Please refer to section on individual vaccines
_____	Today				Please refer to section on individual vaccines
_____	Today				Please refer to section on individual vaccines
_____	Today				Please refer to section on individual vaccines
_____	Today				Please refer to section on individual vaccines

# References

1. Guidelines- Immunization: National Health Mission. Last accessed on June 17, 2023. Available at: <https://www.nhm.gov.in/index1.php?lang=1&level=3&sublinkid=944&lid=378>.
2. Anjana RM, et al. Lancet Diabetes Endocrinol. 2023;11(7):474-489.
3. Vaccines and immunization: What is vaccination? Last accessed on June 28, 2023. Available at: <https://www.who.int/news-room/questions-and-answers/item/vaccines-and-immunization-what-is-vaccination>.
4. Types of Vaccine | India Science, Technology & Innovation - ISTI Portal. Last accessed on June 28, 2023. Available at: <https://www.indiascienceandtechnology.gov.in/covid-19-vaccine/types- vaccine>.
5. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med. 2014;6(6):708-720.
6. Ramasubramanian V. India\_adult\_immunization\_eprint. Last accessed on July 2, 2023. Available at: [https://www.apiindia.org/pdf/progress\\_in\\_medicine\\_2017/mu\\_06.pdf](https://www.apiindia.org/pdf/progress_in_medicine_2017/mu_06.pdf).
7. Bajaj S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries. 2022;42(1):1-143.
8. Guidelines for vaccination in normal adults in India. Indian J Nephrol. 2016;26(Suppl 1):S7-S14.
9. Sharma OP. Indian recommendations for vaccination in older adults. Delhi: Geriatric society of India. 2015.
10. IMA\_IMMUNIZATION\_GUIDELINES\_2018. Last accessed on January 19, 2024. Available at: [https://www.ima-India.org/ima/pdfdata/IMA\\_LifeCourse\\_Immunization\\_Guide\\_2018\\_DEC21.pdf](https://www.ima-India.org/ima/pdfdata/IMA_LifeCourse_Immunization_Guide_2018_DEC21.pdf).
11. Wagh G, Kurian R. Vaccination in Women.; 2014. Last accessed on January 19, 2024. Available at: [https://www.fogsi.org/wp-content/uploads/2015/11/vaccination\\_women.pdf](https://www.fogsi.org/wp-content/uploads/2015/11/vaccination_women.pdf).
12. Good Clinical Practice Recommendations on Preconception Care – GCPR - The Federation of Obstetric & Gynecological Societies of India. Published September 29, 2016. Last accessed on July 2, 2023. Available at: <https://www.fogsi.org/gcpr-preconception-care>.
13. Srivastava RK. CD Alert. Published online 2011. Available at: [https://ncdc.mohfw.gov.in/WriteReadData/linkimages/February\\_Final\\_020862513827.pdf](https://ncdc.mohfw.gov.in/WriteReadData/linkimages/February_Final_020862513827.pdf).
14. Recommended Adult Immunization Schedule for ages 19 years or older, United States, 2024. Published online 2024. Available at: <https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf>.
15. Anthrax Vaccination | CDC. Published April 26, 2023. Accessed March 14, 2024. <https://www.cdc.gov/vaccines/vpd/anthrax/index.html>
16. Research C for BE and. IXCHIQ. FDA. Published online November 9, 2023. Last accessed on November 22, 2023. Available at: <https://www.fda.gov/vaccines-blood-biologics/ixchiq>.

17. Approval\_New. Last accessed on June 24, 2023. Available at: [https://cdsco.gov.in/opencms/opencms/en/Approval\\_new/](https://cdsco.gov.in/opencms/opencms/en/Approval_new/).
18. Paget J, Caini S, et al. Has influenza B/Yamagata become extinct and what implications might this have for quadrivalent influenza vaccines? *Eurosurveillance*. 2022;27(39):2200753.
19. Greenberg RN, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60–64 years of age. *Vaccine*. 2014;25;32(20):2364-74.
20. Dhar R, et al. Clinical practice guidelines 2019: Indian consensus-based recommendations on pneumococcal vaccination for adults. *Lung India: Official Organ of Indian Chest Society*. 2020; 37(Suppl 1):S19.
21. Rabies. Last accessed on July 2, 2023. Available at: <https://www.who.int/news-room/fact-sheets/detail/rabies>.
22. Papi A, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. *New Eng J Med*. 2023;388(7):595-608.
23. Commissioner O of the. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. FDA. Published May 4, 2023. Last accessed on July 2, 2023. Available at: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine>.
24. IHR POE. Last accessed on November 22, 2023. Available at: [https://www.ihpoe.mohfw.gov.in/vaccination\\_centres.php](https://www.ihpoe.mohfw.gov.in/vaccination_centres.php).
25. Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials. *Clin Infect Dis*. 2014;58(4):470-480.
26. Patel MM, Clark AD, Sanderson CFB, Tate J, Parashar UD. Removing the Age Restrictions for Rotavirus Vaccination: A Benefit-Risk Modeling Analysis. *PLOS Med*. 2012;9(10):e1001330.
27. Bansal SB, et al. Pre- and posttransplant vaccination for solid organ transplant recipient and in South Asia-Expert group opinion. *Indian Journal of Transplantation*. 2022;16(Suppl 1):S106-11.
28. Huang CH, et al. Dengue vaccine: an update. *Expert Review of Anti-Infective Therapy*. 2021;19(12):1495-502.
29. Dengue vaccine: India moves closer to getting its first indigenous vaccine. *The Hindu*. Published May 16, 2023. Last accessed on July 1, 2023. Available at: <https://www.thehindu.com/news/national/dengue-vaccine-india-moves-closer-to-getting-its-first-indigenous-vaccine/article66857827.ece>.
30. Leggat DJ, et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. *Science*. 2022;378 (6623):eadd6502.
31. A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants - Full Text View - *ClinicalTrials.gov*. Last accessed on July 1, 2023. Available at: <https://clinicaltrials.gov/ct2/show/NCT05217641>.

32. A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) - Full Text View - ClinicalTrials.gov. Last accessed on July 1, 2023. Available at: <https://clinicaltrials.gov/ct2/show/NCT05414786>.
33. Development Pipeline | Vir Biotechnology. Last accessed on July 1, 2023. Available at: <https://www.vir.bio/pipeline/>.
34. The Arenaviruses. Last accessed on July 1, 2023. Available at: <https://www.hookipapharma.com/our-science/our-arenavirus-platform/>.
35. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial | Nature Medicine. Last accessed on July 1, 2023. Available at: <https://www.nature.com/articles/s41591-022-02060-2>.
36. Dose Escalation Trial of CD40. HIVRI. Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers - Full Text View - ClinicalTrials.gov. Last accessed on July 1, 2023. Available at: <https://clinicaltrials.gov/ct2/show/NCT04842682>.
37. Single-component multilayered self-assembling protein nanoparticles presenting glycan-trimmed uncleaved prefusion optimized envelope trimers as HIV-1 vaccine candidates | Nature Communications. Last accessed on July 1, 2023. Available at: <https://www.nature.com/articles/s41467-023-37742-z>.
38. First-ever malaria vaccine recommendation now published in a position paper and in the WHO guidelines for malaria. Last accessed July 1, 2023. Available at: <https://www.who.int/news/item/04-03-2022-first-ever-malaria-vaccine-recommendation-now-published-in-a-position-paper-and-in-the-who-guidelines-for-malaria>.
39. RTS S. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. *Lancet*. 2015;386(9988):31-45.
40. Parums DV. Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030. *Medical Science Monitor: International Medical Journal of Experimental and Clinical Research*. 2022;28:e939357-1.
41. Draper SJ, et al. Recent advances in recombinant protein-based malaria vaccines. *Vaccine*. 2015;33(52):7433-43.
42. Guidelines on the quality, safety and efficacy of recombinant malaria vaccines targeting the pre-erythrocytic and blood stages of *Plasmodium falciparum*, Annex 3, TRS No 980. Last accessed on July 1, 2023. Available at: <https://www.who.int/publications/m/item/recombinant-malaria-vaccine-annex-3-trs-980>.
43. Van Der Meeren O, et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. *New Eng J Med*. 2018;379(17):1621-34.

44. Mast J. Gates Foundation to fund trial of long-awaited new tuberculosis vaccine candidate. STAT. Published June 28, 2023. Last accessed on July 2, 2023. Available at: <https://www.statnews.com/2023/06/28/tuberculosis-vaccine-gates/>.
45. Rao PN, and Suneetha S. Current situation of leprosy in India and its future implications. Indian Dermatol online journal. 2018;9(2):83.
46. Zika Virus Vaccines | NIH: National Institute of Allergy and Infectious Diseases. Published August 16, 2018. Last accessed on July 2, 2023. Available at: <https://www.niaid.nih.gov/diseases-conditions/zika-vaccines>.
47. Tan M. Norovirus vaccines: Current clinical development and challenges. Pathogens. 2021;10(12):1641.
48. Carreras-Abad C, et al. A vaccine against group B Streptococcus: recent advances. Infection and drug resistance. 2020;29:1263-72.
49. Clegg J, et al. Staphylococcus aureus vaccine research and development: The past, present and future, including novel therapeutic strategies. Frontiers in immunology. 2021;12:705360.
50. Suárez N, et al. Bacterial lysates as immunotherapies for respiratory infections: Methods of preparation. Front in Bioengi Biotechnol. 2020;8:545.
51. Adult Immunization - Frequently Asked Questions. Medindia. Last accessed on January 12, 2024. Available at: <https://www.medindia.net/health/treatment/adult-immunization-faqs.htm>.
52. Vaccines: Basics and Common Questions | CDC. Published April 6, 2022. Last accessed on January 12, 2024. Available at: <https://www.cdc.gov/vaccines/vac-gen/default.htm>.
53. Opri R, et al. True and false contraindications to vaccines. Allergologia et immunopathologia. 2018;46(1):99-104.
54. Pinkbook | General Recommendations | Epidemiology of VPDs | CDC. Published August 17, 2021. Last accessed on January 12, 2024. Available at: <https://www.cdc.gov/vaccines/pubs/pinkbook/genrec.html>.
55. Guide to Contraindications and Precautions to Commonly Used Vaccines for All Ages. Last accessed on January 19, 2024. Available at: <https://www.immunize.org/wp-content/uploads/catg.d/p3072a.pdf>.



Disclaimer: This article reprint is only intended for HealthCare Practitioner (HCP) registered in India. All information published herein is intended and strictly only for informational, educational, academic and/or research purposes and is not intended to substitute for professional medical advice, diagnosis or treatment. The views and opinions expressed in the Book are strictly those of the author and the individuals expressing the same and Pfizer Ltd. ("Pfizer") may not necessarily endorse the same. This Book is confidential and may also be privileged. It is intended solely for the HCP receiving the same. It is hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Pfizer shall not be liable for the improper transmission of this Book or part thereof nor for any damage sustained as a result of the same. Consent has been obtained by Pfizer from the Publishers for publishing the Book. While due care and caution has been taken to ensure that the content here is free from mistakes or omissions, Pfizer makes no representations or warranties of any kind, expressed or implied; as to the content of the Book and /or about the accuracy, completeness or adequacy of its contents and will not be liable for any damages, adverse events, and personal liability arising therefrom. For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory

 **Pfizer Limited**, The Capital - A Wing, 1802, 18<sup>th</sup> floor, Plot No. C-70, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051, India.



GCMA Code: PP-PRV-IND-1166; 01.08.2024